[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1625
1. Li YJ, Wen G, Wang Q: [Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan;29(1):70-1, 74
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms].
  • OBJECTIVE: To investigate the differences in the expression of angiogenesis-related molecules between benign and malignant breast neoplasms.
  • METHODS: Thirty breast cancer patients (33 foci) and 30 with benign breast neoplasms (34 foci) were examined for CD34, vascular endothelial growth factor (VEGF) and Flk-1/KDR expressions using immunohistochemistry.
  • RESULTS: In patients with breast cancer, the microvessels densely distributed around the cancer nest.
  • The microvessel density (MVD) in the cancer patients was significantly higher than that in patients with benign tumors (34.48+/-8.34 vs 18.65+/-4.69, P<0.05).
  • In the breast cancer patients, strong VEGF expression was found in the epithelial cells and vascular endothelial cells around the breast carcinoma, and Flk-1/KDR was also strongly expressed in the vascular endothelial cells.
  • The expressions of VEGF and Flk-1/KDR were hardly detectable in the benign tumors.
  • CONCLUSION: VEGF is an important regulatory factor in promoting breast tumor angiogenesis.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218116.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


2. Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, Kuranami M, Watanabe M, Hayakawa K: ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci; 2005;4(1):35-42
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ADC mapping of benign and malignant breast tumors.
  • PURPOSE: The purpose of this study was to investigate the utility of diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) value in differentiating benign and malignant breast lesions and evaluating the detection accuracy of the cancer extension.
  • MATERIALS AND METHODS: We used DWI to obtain images of 191 benign and malignant lesions (24 benign, 167 malignant) before surgical excision.
  • The ADC values of the benign and malignant lesions were compared, as were the values of noninvasive ductal carcinoma (NIDC) and invasive ductal carcinoma (IDC).
  • RESULTS: The mean ADC value of each type of lesion was as follows: malignant lesions, 1.22+/-0.31 x 10(-3) mm2/s; benign lesions, 1.67+/-0.54 x 10(-3) mm2/s; normal tissues, 2.09+/-0.27 x 10(-3) mm2/s.
  • The mean ADC value of the malignant lesions was statistically lower than that of the benign lesions and normal breast tissues.
  • The sensitivity of the ADC value for malignant lesions with a threshold of less than 1.6 x 10(-3) mm2/s was 95% and the specificity was 46%.
  • A full 75% of all malignant cases exhibited a near precise distribution of low ADC values on ADC maps to describe malignant lesions.
  • CONCLUSIONS: DWI has the potential in clinical appreciation to detect malignant breast tumors and support the evaluation of tumor extension.
  • However, the benign proliferative change remains to be studied as it mimics the malignant phenomenon on the ADC map.
  • [MeSH-major] Algorithms. Artificial Intelligence. Breast Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127252.001).
  • [ISSN] 1347-3182
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Li YJ, Yang L, Xia Q, Wen G: [Hemodynamic changes in benign and malignant breast tumors and the mechanism]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Aug;29(8):1557-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemodynamic changes in benign and malignant breast tumors and the mechanism].
  • OBJECTIVE: To compare the histological morphology, hemodynamics and angiogenesis-related molecules between benign and malignant breast tumor and investigate their variation in different perfusion regions in the same type of tumors.
  • METHODS: Thirty patients with malignant breast carcinoma and 30 with breast fibroadenoma underwent contrast-enhanced ultrasound examination with time-intensity quantitative analysis.
  • RESULTS: The time-intensity curve (TIC) of malignant tumor group was characterized by rapid ascent and slow descent, while that of the benign group presented with slow ascent and rapid descent.
  • The AUC and WOT of the malignant tumor group were significantly higher than those of the benign group, while the PI and TTP showed no significant difference.
  • In malignant tumor group, PI, AUC and WOT on the margin of the foci were significantly higher those of the inside region, while TTP showed a reverse pattern.
  • No significant differences were found in the perfusion parameters between the inside and outside of the foci in the benign group.
  • The distribution of CD34 was heterogeneous in breast carcinoma, and the micro-vessels were densely distributed especially on the margin of the cancer nest.
  • The microvessel density of the malignant group (34.48-/+8.34) was significantly higher than that of the benign group (18.65-/+4.69).
  • Diffuse or focal high VEGF expression was found on the margin of the cancer nest and necrotic tissue, but hardly detected in the benign group.
  • Flk-1/KDR expressed diffusely or focally in breast carcinoma with especial high expression on the margin of the cancer nest and necrotic tissue, but was virtually undetectable in the benign group.
  • CONCLUSION: The perfusion pattern, TIC, mean perfusion parameter and variation of the regional perfusion parameters provide valuable evidence for differential diagnoses between benign and malignant breast tumors.
  • Molecular imaging targeting VEGF and Flk-1/KD shed light on new approaches to early diagnosis of breast carcinoma.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Hemodynamics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726291.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


Advertisement
4. Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK: CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol; 2005 Nov;58(11):1185-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.
  • BACKGROUND/AIMS: CD44s, the standard form of CD44, has been shown to be downregulated during malignant transformation of breast cancers.
  • It has also been reported recently to be a useful marker in differentiating between benign and malignant papillary lesions of the breast, with high expression in the former.
  • CD44s expression in benign and malignant papillary lesions was evaluated.
  • METHODS: CD44s expression was assessed by immunohistochemistry in 101 benign papillomas and 59 papillary carcinomas (seven invasive papillary carcinomas, 41 papillary ductal carcinomas in situ, and 11 ductal carcinomas involving papillomas).
  • Using CD44s positive staining to differentiate between benign and malignant papillary lesions gives a sensitivity, specificity, and accuracy of 45%, 92%, and 62%, respectively.
  • CONCLUSIONS: CD44s may be useful as an adjunct in the evaluation of morphologically problematic cases of papillary lesion of the breast.
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma, Intraductal / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2004 Apr;19(2):465-71 [15024707.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1665-70 [15274338.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):211-31 [15339042.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):23-31 [15385106.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):276-89 [2450059.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):939-47 [1698341.001]
  • [Cites] Cancer Cells. 1991 Sep;3(9):347-50 [1721518.001]
  • [Cites] J Cell Biol. 1992 Aug;118(4):971-7 [1380003.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22 [1384226.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Curr Top Microbiol Immunol. 1993;184:47-63 [7508842.001]
  • [Cites] Bioessays. 1995 Jan;17(1):17-24 [7535522.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5424-33 [7585612.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(3):307-313 [8573713.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):862-4 [10690183.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(3):125-35 [8781700.001]
  • [Cites] Clin Exp Metastasis. 1996 Oct;14(5):434-9 [8871537.001]
  • [Cites] Histopathology. 1998 Aug;33(2):107-16 [9762542.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):45-50 [10071234.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):625-32 [15832086.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(1):23-9 [11245336.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2539-46 [11745187.001]
  • [Cites] J Pathol. 2001 Nov;195(4):415-21 [11745672.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):34-9 [11893033.001]
  • [Cites] Histopathology. 2003 Jun;42(6):546-54 [12786890.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):548-54 [12712335.001]
  • [Cites] Pol J Pathol. 2003;54(4):243-7 [14998292.001]
  • [Cites] Genomics. 1995 Nov 1;30(1):115-7 [8595891.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):513-8 [8621236.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):259-61 [8654608.001]
  • (PMID = 16254109.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44S antigen
  • [Other-IDs] NLM/ PMC1770758
  •  go-up   go-down


5. Egorov V, Kearney T, Pollak SB, Rohatgi C, Sarvazyan N, Airapetian S, Browning S, Sarvazyan A: Differentiation of benign and malignant breast lesions by mechanical imaging. Breast Cancer Res Treat; 2009 Nov;118(1):67-80
MedlinePlus Health Information. consumer health - Health Checkup.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of benign and malignant breast lesions by mechanical imaging.
  • The objective of this study is the clinical evaluation of breast mechanical imager for breast lesion characterization and differentiation between benign and malignant lesions.
  • The breast mechanical imager includes a probe with pressure sensor array, an electronic unit providing data acquisition from the pressure sensors and communication with a touch-screen laptop computer.
  • We have developed an examination procedure and algorithms to provide assessment of breast lesion features such as hardness related parameters, mobility, and shape.
  • A statistical Bayesian classifier was constructed to distinguish between benign and malignant lesions by utilizing all the listed features as the input.
  • Clinical results for 179 cases, collected at four different clinical sites, have demonstrated that the breast mechanical imager provides a reliable image formation of breast tissue abnormalities and calculation of lesion features.
  • Malignant breast lesions (histologically confirmed) demonstrated increased hardness and strain hardening as well as decreased mobility and longer boundary length in comparison with benign lesions.
  • Statistical analysis of differentiation capability for 147 benign and 32 malignant lesions revealed an average sensitivity of 91.4% and specificity of 86.8% with a standard deviation of +/-6.1%.
  • The area under the receiver operating characteristic curve characterizing benign and malignant lesion discrimination is 86.1% with the confidence interval ranging from 80.3 to 90.9%, with a significance level of P = 0.0001 (area = 50%).
  • The multisite clinical study demonstrated the capability of mechanical imaging for characterization and differentiation of benign and malignant breast lesions.
  • We hypothesize that the breast mechanical imager has the potential to be used as a cost effective device for cancer diagnostics that could reduce the benign biopsy rate, serve as an adjunct to mammography and to be utilized as a screening device for breast cancer detection.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biometrika. 1951 Jun;38(1-2):219-47 [14848124.001]
  • [Cites] JAMA. 1999 Oct 6;282(13):1270-80 [10517431.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):345-61 [15537577.001]
  • [Cites] Radiology. 2005 May;235(2):396-401 [15770039.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Apr;5(2):239-52 [15877522.001]
  • [Cites] J Biomed Inform. 2005 Oct;38(5):404-15 [16198999.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1773-83 [16169887.001]
  • [Cites] Radiology. 2006 Feb;238(2):425-37 [16436810.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1090-6 [16457689.001]
  • [Cites] Radiology. 2006 May;239(2):341-50 [16484352.001]
  • [Cites] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Jul;35(4):444-7 [16924712.001]
  • [Cites] Ultrasound Obstet Gynecol. 2006 Sep;28(3):335-40 [16909438.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):444-9 [16978946.001]
  • [Cites] Radiology. 2007 Sep;244(3):708-17 [17709826.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):384-92 [17882648.001]
  • [Cites] Plast Surg Nurs. 2007 Jul-Sep;27(3):128-33; quiz 134-5 [17901821.001]
  • [Cites] Radiology. 2007 Nov;245(2):401-10 [17940302.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Ultrasound Med Biol. 2008 Sep;34(9):1373-86 [18395961.001]
  • [Cites] IEEE Trans Med Imaging. 2008 Sep;27(9):1275-87 [18753043.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):971-6 [10861308.001]
  • [Cites] Urology. 2001 Dec;58(6):1059-63 [11744495.001]
  • [Cites] Breast Cancer Res Treat. 2002 Nov;76(1):73-81 [12408378.001]
  • [Cites] J Med Screen. 2003;10(1):16-21 [12790311.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):199-206 [12825854.001]
  • [Cites] Science. 1988 Jun 3;240(4857):1285-93 [3287615.001]
  • [Cites] Int J Med Inform. 1998 Apr;49(2):195-216 [9741894.001]
  • [Cites] Ultrason Imaging. 1998 Oct;20(4):260-74 [10197347.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):327-44 [15537576.001]
  • (PMID = 19306059.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091392; United States / NCI NIH HHS / CA / CA091392-05; United States / NCI NIH HHS / CA / R44 CA091392-03; United States / NCI NIH HHS / CA / R43 CA091392; United States / NCI NIH HHS / CA / R44 CA091392-05; United States / NCI NIH HHS / CA / R44 CA091392-04; United States / NCI NIH HHS / CA / R44 CA091392; United States / NCI NIH HHS / CA / CA091392-03
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS164459; NLM/ PMC2803347
  •  go-up   go-down


6. Pieta B, Opala T, Wilczak M, Grodecka-Gazdecka S, Kramer L, Samulak D, Wieznowska-Maczyńska K: Past obstetric history and risk of malignant breast neoplasms. Eur J Gynaecol Oncol; 2008;29(4):374-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Past obstetric history and risk of malignant breast neoplasms.
  • Many studies indicate hormonal disorders as a crucial reason for breast pathology.
  • They are also probably responsible for the development of benign neoplasms and play a role in the origin and development of breast carcinoma.
  • Although the mammary gland is under the influence of many steroid and peptide hormones such as thyroid hormones, prolactin, growth hormone, glucocorticosteroids, it is estrogen that plays an important role in the development of breast cancer.
  • The purpose of the study was to analyze the obstetrical past of patients and the potential influence on the risk of developing malignant breast neoplasms.
  • The participants in the study were healthy women with no changes in mammary glands (control group) and women with diagnosed malignant or benign breast neoplasms (study group).
  • Hormonal disorders in childhood and puberty symptoms of early menarche play a crucial role in increasing the risk of malignant breast neoplasms.
  • In women who experienced one or more miscarriages the risk of malignant breast neoplasms is significantly increased.
  • On the basis of our study we calculated the odds ratio (OR) of malignant breast neoplasms among women who during lactation experienced problems needing medical intervention (OR = 2.25; 95% CI, 1.20-4.19) in comparison to women who experienced no problems).
  • [MeSH-major] Breast Neoplasms / epidemiology. Reproductive History
  • [MeSH-minor] Adult. Aged. Breast Diseases. Case-Control Studies. Confidence Intervals. Estrogens. Female. Humans. Middle Aged. Odds Ratio. Poland / epidemiology. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714573.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


7. Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, Semmes OJ, Perry RR, Drake RR: Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg; 2007 May;204(5):1065-71; discussion 1071-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum biomarkers to differentiate benign and malignant mammographic lesions.
  • BACKGROUND: Mammographic screening has increased detection of earlier-stage breast cancers and has decreased mortality from breast cancer.
  • A Breast Imaging-Reporting and Data System (BIRADS) 4 classification prompts a biopsy that most often reveals benign disease.
  • Our objective was to determine if serum protein-expression profiles could be used to differentiate between benign and malignant mammographic lesions.
  • Sera from 92 subjects were randomly selected to form benign (n = 46) and cancer (n = 46) cohorts.
  • The MALDI-TOF spectra analysis yielded 273 peaks, with 14 peaks expressed differentially (p < 0.05) between the cancer and benign cohorts.
  • CONCLUSIONS: MALDI-TOF protein-expression profiles generated from BIRADS 4 sera could be used to distinguish between benign and malignant mammographic lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481542.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA98028
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


8. Sabaté JM, Gómez A, Torrubia S, Blancas C, Sánchez G, Alonso MC, Lerma E: Evaluation of breast involvement in relation to Cowden syndrome: a radiological and clinicopathological study of patients with PTEN germ-line mutations. Eur Radiol; 2006 Mar;16(3):702-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of breast involvement in relation to Cowden syndrome: a radiological and clinicopathological study of patients with PTEN germ-line mutations.
  • We describe the clinical, radiological, and pathological findings of the diverse benign and malignant breast neoplasms found in association with Cowden syndrome.
  • Patients with Cowden syndrome had a substantially increased risk of breast carcinoma.
  • We find that 33% of the patients in our study population with Cowden disease have developed breast carcinoma to date.
  • An association between Cowden disease and multiple tubular adenomas or breast hamartomas was found in two patients, suggesting a genetic origin.
  • PTEN germ-line mutations were found in all four patients presenting with relevant benign or malignant breast pathology.
  • [MeSH-major] Breast Neoplasms / genetics. Germ-Line Mutation. Hamartoma Syndrome, Multiple / genetics. PTEN Phosphohydrolase / genetics

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2004 Sep;14 (9):1647-53 [15083333.001]
  • [Cites] Breast Cancer Res Treat. 1998 Sep;51(1):1-15 [9877025.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] J Am Acad Dermatol. 1984 Dec;11(6):1127-41 [6512057.001]
  • [Cites] Histopathology. 1982 Sep;6(5):539-47 [6890520.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):349-51 [9930780.001]
  • [Cites] Hum Pathol. 1998 Jan;29(1):47-53 [9445133.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):757-61 [10701621.001]
  • [Cites] Annu Rev Med. 1998;49:425-36 [9509273.001]
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Radiology. 2002 Nov;225(2):519-26 [12409590.001]
  • [Cites] Am J Surg Pathol. 1991 Aug;15(8):722-31 [2069210.001]
  • [Cites] J Invest Dermatol. 2002 Apr;118(4):639-44 [11918710.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):27-31 [7712647.001]
  • (PMID = 16208511.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human
  •  go-up   go-down


9. Schem Ch, Bauerschlag DO, Meinhold-Heerlein I, Fischer D, Friedrich M, Maass N: [Benign and borderline tumors of the ovary]. Ther Umsch; 2007 Jul;64(7):369-74
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign and borderline tumors of the ovary].
  • [Transliterated title] Benigne und Borderline-Tumoren des Ovars.
  • The suspected diagnosis concerning benign or malignant lesions, should take the palpable and sonographic feature, as well as the information from the patients medical history (e.g. family history of malignant diseases (BRCA 1/2 mutations) into account.
  • They are mostly normal follicle cysts, but may also be a tumor of low malignant potential (LMP-tumor) or even an invasive cancerous lesion.
  • 20-30% of all ovarian tumors are malignant and by the time of primary diagnosis already in a about 60-70% incurable due to intraabdominal dissemination.
  • Benign or malignant lesions may occur in every age group.
  • Ovarian tumors at infantile age are malignant in about 15%.
  • Most malignant tumors occur between the age of 50 to 70.
  • Malignant ovarian lesions represent about 15-30% of all genital malignant tumors.
  • Hormonal contraceptives, pregnancy and breast feeding seem to be protective.
  • This compilation overviews the spectrum of benign and low malignant potential tumors of the ovary and their different tissues of origin.
  • [MeSH-major] Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Ovarian Cysts / diagnosis. Ovarian Cysts / radiography. Ovarian Cysts / ultrasonography. Ovary / pathology. Palpation. Time Factors. Tomography, X-Ray Computed. Ultrasonography, Doppler

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948753.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 22
  •  go-up   go-down


10. Kim JY, Han BK, Choe YH, Ko YH: Benign and malignant mucocele-like tumors of the breast: mammographic and sonographic appearances. AJR Am J Roentgenol; 2005 Nov;185(5):1310-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant mucocele-like tumors of the breast: mammographic and sonographic appearances.
  • OBJECTIVE: The purpose of this study was to analyze and compare the mammographic and sonographic appearances of benign and malignant mucocele-like tumors.
  • CONCLUSION: The mammographic appearance of mucocele-like tumor of the breast is characterized as pleomorphic calcifications, often increasing in number.
  • Microcalcifications in malignant mucocele-like tumors extended over a wider area than those in benign mucocele-like tumors.
  • [MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Fibrocystic Breast Disease / radiography. Fibrocystic Breast Disease / ultrasonography. Mucocele / radiography. Mucocele / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247155.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Varela C, Karssemeijer N, Hendriks JH, Holland R: Use of prior mammograms in the classification of benign and malignant masses. Eur J Radiol; 2005 Nov;56(2):248-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of prior mammograms in the classification of benign and malignant masses.
  • The purpose of this study was to determine the importance of using prior mammograms for classification of benign and malignant masses.
  • The radiologists' performances in classifying benign and malignant masses without and with previous mammograms were evaluated with receiver operating characteristic (ROC) analysis.
  • [MeSH-major] Breast Neoplasms / classification. Mammography
  • [MeSH-minor] Aged. Area Under Curve. Biopsy. Breast Cyst / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal, Breast / radiography. Data Display. Female. Fibroadenoma / radiography. Fibrocystic Breast Disease / radiography. Follow-Up Studies. Humans. Hyperplasia. Image Processing, Computer-Assisted / methods. Mass Screening. Middle Aged. Observer Variation. Population Surveillance. ROC Curve

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890483.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


12. Meisner AL, Fekrazad MH, Royce ME: Breast disease: benign and malignant. Med Clin North Am; 2008 Sep;92(5):1115-41, x
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast disease: benign and malignant.
  • Breast diseases, both benign and malignant, are common.
  • Typically, young women present with more benign pathologies; however, breast malignancies can occur in young women, especially in those harboring mutations in the BRCA genes, other inherited genetic syndromes associated with increased risk of breast cancer, or familial predisposition for breast cancer.
  • In all women aged 40 and over presenting with abnormalities of the breast, a primary breast cancer should be ruled out because it is the leading cancer among women in developed countries.
  • [MeSH-major] Breast Diseases. Breast Neoplasms

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721655.001).
  • [ISSN] 0025-7125
  • [Journal-full-title] The Medical clinics of North America
  • [ISO-abbreviation] Med. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


13. Mergenthaler U, Heymanns J, Köppler H, Thomalla J, van Roye C, Weide R: Evaluation of psycho-social distress in patients treated in a community-based oncology group practice in Germany. J Clin Oncol; 2009 May 20;27(15_suppl):e20577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were classified into the disease groups solid tumors, hematological neoplasms, benign hematological diseases and other non-malignant diseases.
  • Patients with other non-malignant diseases (81% autoimmune diseases or hereditary hemochromatosis) showed the highest average distress level of 5.2.
  • Breast cancer patients stated a distress level of 5.2.
  • CONCLUSIONS: The study shows that cancer patients do not necessarily show higher distress than patients with severe non-malignant diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961101.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Chang YW, Kwon KH, Goo DE, Choi DL, Lee HK, Yang SB: Sonographic differentiation of benign and malignant cystic lesions of the breast. J Ultrasound Med; 2007 Jan;26(1):47-53
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic differentiation of benign and malignant cystic lesions of the breast.
  • OBJECTIVE: The purpose of this study was to subdivide the types of sonographic findings of benign versus malignant cystic masses and to determine appropriate patient care according to the sonographic findings with pathologic correlation.
  • METHODS: The sonographic findings of 175 symptomatic cystic breast lesions were pathologically proven and reviewed retrospectively.
  • Sonographic findings were compared with the pathologic results and were evaluated according to the incidence of benign and malignant masses.
  • RESULTS: All 23 type I, 15 type II, 22 type III, and 35 type IV cases were pathologically proven to be benign.
  • Seven (25.9%) of the 27 type V cases and 33 (62.3%) of the 53 type VI cases were proven to be malignant.
  • We analyzed the shapes and margins of 80 cases of cystic masses with a solid component (types V and VI); 16 (44%) of 36 sonographically circumscribed masses were malignant.
  • CONCLUSIONS: Because the sonographically detected simple cysts (type I), clustered cysts (type II), and cysts with thin septa (type III) were all benign, annual routine follow-up appears reasonable.
  • [MeSH-major] Breast Cyst / ultrasonography. Breast Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17182708.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kim TH, Kang DK, Kim SY, Lee EJ, Jung YS, Yim H: Sonographic differentiation of benign and malignant papillary lesions of the breast. J Ultrasound Med; 2008 Jan;27(1):75-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic differentiation of benign and malignant papillary lesions of the breast.
  • OBJECTIVE: The purpose of this study was to evaluate sonographic findings of breast papillary lesions and the effectiveness of the American College Radiology Breast Imaging Reporting and Data System sonographic assessment system for differentiation of benign and malignant papillary lesions.
  • METHODS: We retrospectively reviewed breast sonographic findings of 46 surgically proven benign papillomas and 22 papillary carcinomas.
  • Sonographic findings were analyzed according to the Breast Imaging Reporting and Data System classification.
  • RESULTS: The shape of the lesion was round or oval in 33 benign lesions (71.7%) and 13 papillary carcinomas (61.9%).
  • As for the margin, a circumscribed margin was found in 31 benign papillomas (67.4%) and 12 malignant lesions (57.1%).
  • Fourteen benign papillomas (30.5%) and 12 papillary carcinomas (57.1%) showed a complex echo pattern.
  • It was more frequently observed in malignant lesions; however, it was not statistically significant (P = .09).
  • A nonparallel orientation, an echogenic halo, posterior acoustic enhancement, and associated microcalcification were more frequently found in malignant than in benign lesions (P < .05).
  • When the presence of any suspicious sonographic feature (nonparallel orientation, echogenic halo, posterior enhancement, or calcification) was considered to indicate malignancy, interpretation of the sonographic features gave sensitivity of 85.7%, specificity of 64.9%, a positive predictive value of 47.4%, and a negative predictive value of 92.5% for detection of malignant papillary lesions.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Carcinoma, Papillary / ultrasonography. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096733.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Dugina VB, Chipysheva TA, Ermilova VD, Gabbiani D, Chaponnier C, Vasil'ev IuM: [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells]. Arkh Patol; 2008 Mar-Apr;70(2):28-31
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells].
  • The distribution of beta- and gamma-cytoplasmic actins was compared in the normal cells and dysplastic malignant breast epithelial cells.
  • The authors' findings suggest that specific monoclonal antibodies to beta- and gamma-cytoplasmic actins may be used as supplementary markers that can differentiate benign and malignant breast neoplasms.
  • [MeSH-major] Actins / metabolism. Breast Neoplasms / metabolism. Fibroadenoma / metabolism. Fibrocystic Breast Disease / metabolism. Mammary Glands, Human / metabolism. Neoplasm Proteins / metabolism. Papilloma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540438.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  •  go-up   go-down


17. Giorgi Rossi P, Federici A, Farchi S, Chini F, Barca A, Guasticchi G, Borgia P: The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy. J Med Screen; 2006;13(3):123-8
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy.
  • In this study, we compare the incidences of treatments for benign and malignant neoplasms in the two groups.
  • We linked all incident cases of surgery for benign and malignant breast neoplasms, from the Hospital Information System (1999-2003) to the Mammographic Screening Information System (1999-2001).
  • We calculated incidence, adjusted for age and standardized breast cancer mortality ratio in each area of residence, for benign and malignant neoplasms surgery in non-yet-contacted and contacted woman.
  • RESULTS: The target population in Lazio is 681,000; 116,000 women were contacted during the study period and 3252 malignant and 1566 benign neoplasms were surgically treated.
  • Annual incidence was, respectively, 2.0/1000 and 1.1/1000 for malignant and benign neoplasms in women not contacted, and, respectively, 2.9/1000 and 1.1/1000 in the contacted population.
  • About one-half of the surgeries for benign neoplasms in compliant women were treated against the recommendation of the screening programme.
  • CONCLUSIONS: The implementation of the screening programme did not increase the incidence of treatment for benign neoplasms, and detected 50% more malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / epidemiology. Mammography. Mass Screening. Patient Compliance / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007652.001).
  • [ISSN] 0969-1413
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Herrera Espiñeira C, Fernández Valdivia J, López-Cuervo JE, Martínez Tapias J: Textural analysis in the diagnosis of benign and malignant breast cells. Anal Quant Cytol Histol; 2007 Dec;29(6):365-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Textural analysis in the diagnosis of benign and malignant breast cells.
  • OBJECTIVE: To study the discriminatory capacity of textural variables to classify the nuclei of breast tumor cells as benign or malignant, using a statistical approach.
  • The sample comprised 95 cases of malignant lesions and 47 cases of benign lesions (approximately 25 nuclei per case), and 27 textural variables were measured.
  • RESULTS: The variance in gray levels was the most decisive variable in the CART analysis, correctly classifying 57% and 97% of benign and malignant cases, respectively.
  • Discriminant analysis yielded the best results, correctly classifying 79% and 85% of benign and malignant cases, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225392.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Chowdary MV, Kumar KK, Kurien J, Mathew S, Krishna CM: Discrimination of normal, benign, and malignant breast tissues by Raman spectroscopy. Biopolymers; 2006 Dec 5;83(5):556-69
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrimination of normal, benign, and malignant breast tissues by Raman spectroscopy.
  • Breast cancers are the leading cancers among females.
  • Hence development of more reliable screening and diagnosis methodology is of considerable interest in breast cancer management.
  • Raman spectra of normal, benign, and malignant breast tissue show significant differences.
  • Spectral differences between normal and diseased breast tissues are more pronounced than between the two pathological conditions, malignant and benign tissues.
  • Based on spectral profiles, the presence of lipids (1078, 1267, 1301, 1440, 1654, 1746 cm(-1)) is indicated in normal tissue and proteins (stronger amide I, red shifted DeltaCH2, broad and strong amide III, 1002, 1033, 1530, 1556 cm(-1)) are found in benign and malignant tissues.
  • The major differences between benign and malignant tissue spectra are malignant tissues seem to have an excess of lipids (1082, 1301, 1440 cm(-1)) and presence of excess proteins (amide I, amide III, red shifted DeltaCH2, 1033, 1002 cm(-1)) is indicated in benign spectra.
  • These results further support the efficacy of Raman spectroscopic methods in discriminating normal and diseased breast tissues.
  • [MeSH-major] Breast / cytology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Neoplasms / diagnosis. Neoplasms / pathology. Spectrum Analysis, Raman

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 16897764.001).
  • [ISSN] 0006-3525
  • [Journal-full-title] Biopolymers
  • [ISO-abbreviation] Biopolymers
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Bhalla A, Manjari M, Kahlon SK, Kumar P, Kalra N: Cytokeratin 5/6 expression in benign and malignant breast lesions. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):676-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin 5/6 expression in benign and malignant breast lesions.
  • In breast tissue, the luminal epithelial cells express CK 8/18, CK 7 and CK 19, while basal/myoepithelial cells express CK 5/6, CK 14 and CK 17.
  • MATERIAL AND METHODS: Immunohistochemical staining for cytokeratin 5/6 was applied on cell block sections of 23 cases of benign and 25 cases of malignant breast lesions using avidin biotin peroxidase technique.
  • RESULT: All benign lesions showed positive immunoreaction, with the staining index varying from 6-9, except lactating adenoma.
  • The malignant lesions comprised three cases of ductal carcinoma in situ (DCIS) and 22 cases of infiltrating ductal carcinoma, not otherwise specified, IDC (NOS).
  • Among the IDC (NOS) lesions, six cases of grade III breast carcinoma exhibited a positive immunohistochemical reaction, the staining index of which varied from 2-6.
  • The staining reaction in the malignant lesions was only cytoplasmic and the intensity was significantly less than that of benign lesions.
  • CONCLUSION: CK 5/6 expression breast carcinoma implies a 'basal like' molecular phenotype and is associated with poor prognosis.
  • This antibody is also used as a component of panels to differentiate benign and malignant breast lesions.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Gene Expression. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045391.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Keratin-5; 0 / Keratin-6
  •  go-up   go-down


21. Barceló J, Vilanova JC, Albanell J, Ferrer J, Castañer F, Viejo N, Argelaguet M: [Breast MRI: the usefulness of diffusion-weighted sequences for differentiating between benign and malignant lesions]. Radiologia; 2009 Sep-Oct;51(5):469-76
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast MRI: the usefulness of diffusion-weighted sequences for differentiating between benign and malignant lesions].
  • [Transliterated title] Resonancia magnética de mama: utilidad de la difusión para diferenciar entre lesiones benignas y malignas.
  • OBJECTIVE: To evaluate the usefulness of diffusion-weighted MRI sequences and of the apparent diffusion coefficient (ADC) to differentiate between benign and malignant breast lesions.
  • MATERIAL AND METHODS: We prospectively studied 88 patients (aged 31 to 79 years) with 94 lesions (80 malignant and 14 benign) who were referred for preoperative local staging.
  • RESULTS: The mean value of the ADC for malignant lesions (1.12+/-0.25x10(-3)mm(2)/s) was significantly lower (p<0.001) than for benign lesions (1.61+/-0.52x10(-3)mm(2)/s).
  • CONCLUSION: Diffusion-weighted sequences provide additional information in breast MRI that is useful for differentiating between benign and malignant lesions, thus improving the specificity of the technique.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647840.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


22. Papachristopoulou G, Avgeris M, Scorilas A: Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost; 2009 Feb;101(2):381-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and study of KLK4 in benign and malignant breast tumours.
  • The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours.
  • Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens.
  • Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients.
  • ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Kallikreins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Cell Line, Tumor. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Prognosis. RNA, Messenger / analysis. ROC Curve. Receptors, Progesterone / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190825.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Progesterone; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


23. Li YJ, Wen G, Yang L, Zhang XL: [Heterogeneity of angioarchitecture and their hemodynamic changes in benign and malignant breast tumors]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):24-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Heterogeneity of angioarchitecture and their hemodynamic changes in benign and malignant breast tumors].
  • OBJECTIVE: To explore the differences between the angioarchitecture, hemodynamics, ultrastructure of neovasculr endothelial cells, and vascular distribution in different perfusion regions in benign and malignant breast tumors.
  • METHODS: 30 cases of breast carcinoma (33 lesions) and 30 cases of breast fibroadenoma (34 lesions) were examined by contrast enhanced microvascular imaging (MVI), and perfusion indexes were collected both inside and at the margin of each focus according to time-intensity quantitative analysis, including peak intensity (PI), area under the curve (AUC), time to peak (TTP) and wash-out time (WOT).
  • Most of the curves of malignant group (87.9%, 29/33) ascended rapidly and dropped slowly while those of the benign group (79.4%, 27/34) ascended slowly and dropped rapidly.
  • The AUC and WOT of malignant tumor group were significantly higher than those of benign group, while the PI and TTP had statistically no significant difference.
  • In the malignant tumor group, PI, AUC and WOT collected from the margin of foci were significantly different from those collected inside the foci, however, there was no significant difference in the benign group.
  • The ultrastructure of endothelial cells in the newly formed blood vessels of malignant group showed strong ability to divide, which was different from normal endothelium cells.
  • CONCLUSION: The perfusion pattern, mode of time-intensity curve, mean perfusion parameter and variation of regional perfusion parameters provide a valuable diagnostic basis in distinguishing benign and malignant breast tumors.
  • [MeSH-major] Breast Neoplasms / blood supply. Carcinoma, Ductal, Breast / blood supply. Fibroadenoma / blood supply. Hemodynamics. Neovascularization, Pathologic / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538864.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Contrast Media
  •  go-up   go-down


24. Cho N, Moon WK, Kim HY, Chang JM, Park SH, Lyou CY: Sonoelastographic strain index for differentiation of benign and malignant nonpalpable breast masses. J Ultrasound Med; 2010 Jan;29(1):1-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonoelastographic strain index for differentiation of benign and malignant nonpalpable breast masses.
  • OBJECTIVE: The purpose of this study was to evaluate the diagnostic potential of the sonoelastographic strain index for differentiation of nonpalpable breast masses.
  • METHODS: Ninety-nine nonpalpable breast masses (79 benign and 20 malignant) in 94 women (mean age, 45 years; range, 21-68 years) who had been scheduled for a sonographically guided core biopsy were examined with B-mode sonography and sonoelastography.
  • Radiologists who had performed the biopsies analyzed the B-mode sonograms and provided American College of Radiology Breast Imaging Reporting and Data System categories.
  • RESULTS: The mean strain index values +/- SD were 6.57 +/- 6.62 (range, 1.29-28.69) in malignant masses and 2.63 +/- 4.57 (range, 0.54-38.76) in benign masses (P = .019).
  • CONCLUSIONS: The strain index based on the fat to lesion strain ratio has diagnostic performance comparable with that of B-mode sonography for differentiation of benign and malignant breast masses.
  • [MeSH-major] Adipose Tissue / physiopathology. Adipose Tissue / ultrasonography. Breast Neoplasms / physiopathology. Breast Neoplasms / ultrasonography. Elasticity Imaging Techniques / methods. Image Interpretation, Computer-Assisted / methods. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040770.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M, Chatzipantelis P: Expression of c-kit in common benign and malignant breast lesions. Tumori; 2010 Nov-Dec;96(6):978-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit in common benign and malignant breast lesions.
  • In recent years, the role of c-kit in the development of preinvasive and invasive breast carcinomas has been investigated.
  • The aim of our study was to detect c-kit expression in the entire spectrum of common benign and malignant breast lesions in correlation with a well-studied myoepithelial or stem-cell like marker (p63).
  • METHODS AND STUDY DESIGN: We evaluated 270 cases of benign and malignant breast lesions including fibrocystic disease, fibroadenoma, sclerosing adenosis, atypical ductal hyperplasia, ductal/lobular carcinoma in situ, and ductal/lobular/mixed type carcinoma.
  • RESULTS: c-kit was highly expressed (85.3%) in benign lesions (fibrocystic disease, sclerosing adenosis, fibroadenoma), and p63 expression was 95.5% in the aforementioned lesions. c-kit distribution in preinvasive and invasive lesions was as follows: ductal/lobular carcinoma in-situ, 43%/35%; ductal/lobular carcinoma, 36%/39%; and mixed type carcinoma, 20%.
  • c-kit was highly expressed in myofibroblast/fibroblast cells only in grade III ductal/lobular carcinomas. c-kit was totally absent in stromal cells in benign lesions and in situ carcinomas whereas expression was weak in grade I and II carcinomas.
  • CONCLUSIONS: Combined overexpression of c-kit and p63 is indicative of benign breast lesions.
  • In contrast, there is reduced expression of c-kit in in situ and invasive breast carcinomas, with simultaneous overexpression in the stromal cells.
  • This suggests that c-kit may play a role in breast cancer progression.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast / pathology. Breast Diseases / metabolism. Breast Diseases / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroblasts / metabolism. Fibrocystic Breast Disease / metabolism. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia / metabolism. Immunohistochemistry. Membrane Proteins / metabolism. Sclerosis / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21388062.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


26. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • Salivary gland-type neoplasms of the breast are uncommon and comprise numerous entities analogous to that more commonly seen in salivary glands.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • Another family of salivary gland-type mammary epithelial neoplasms is devoid of myoepithelial cells.
  • The number of cases of salivary gland-type mammary neoplasms in the published data is constantly increasing but some of the rarest subtypes like polymorphous low-grade adenocarcinoma and oncocytic carcinoma are "struggling" to become clinically relevant entities in line with those occurring more frequently in salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


27. Fabian H, Thi NA, Eiden M, Lasch P, Schmitt J, Naumann D: Diagnosing benign and malignant lesions in breast tissue sections by using IR-microspectroscopy. Biochim Biophys Acta; 2006 Jul;1758(7):874-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing benign and malignant lesions in breast tissue sections by using IR-microspectroscopy.
  • To illustrate the potential of this spectroscopic methodology in breast cancer research, we have acquired IR-microspectroscopic data from benign and malignant lesions in breast tissue sections by point microscopy with spot sizes of 30-40 microm.
  • Four classes of distinct breast tissue spectra were defined and stored in the data base: fibroadenoma (a total of 1175 spectra from 14 patients), ductal carcinoma in situ (a total of 1349 spectra from 8 patients), connective tissue (a total of 464 spectra), and adipose tissue (a total of 146 spectra).
  • Based on these results, the potential of the IR-microspectroscopic approach for diagnosing breast tissue lesions is discussed.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Fibroadenoma / diagnosis. Spectrophotometry, Infrared / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16814743.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Ren Z, Shin A, Cai Q, Shu XO, Gao YT, Zheng W: IGFBP3 mRNA expression in benign and malignant breast tumors. Breast Cancer Res; 2007;9(1):R2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGFBP3 mRNA expression in benign and malignant breast tumors.
  • INTRODUCTION: Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk.
  • METHODS: To understand the role of IGFBP-3 in breast tumorigenesis, we investigated IGFBP3 mRNA expression levels in benign and malignant breast tumors and their adjacent normal tissues using real-time quantitative PCR.
  • RESULTS: Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001).
  • IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors.
  • Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue.
  • There were no apparent associations of IGFBP3 expression in cancer tissues with either overall survival or disease-free survival in a cohort of 521 patients with breast cancer.
  • CONCLUSION: Our findings suggest that the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):295-300 [10861490.001]
  • [Cites] Breast Cancer Res Treat. 2007 Sep;105(1):55-61 [17066319.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):448-53 [11054675.001]
  • [Cites] Microsc Res Tech. 2002 Oct 1;59(1):12-22 [12242693.001]
  • [Cites] J Endocrinol. 2002 Oct;175(1):19-31 [12379487.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2969-76 [12433918.001]
  • [Cites] J Clin Pathol. 2003 Aug;56(8):599-604 [12890810.001]
  • [Cites] Cancer Biol Ther. 2003 Nov-Dec;2(6):630-5 [14688466.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):836-9 [14871809.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1950-6 [15070968.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5100-3 [1381277.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5204-7 [1382838.001]
  • [Cites] J Biol Chem. 1993 Jul 15;268(20):14964-71 [7686909.001]
  • [Cites] J Cell Biochem. 1993 Jun;52(2):196-205 [7690042.001]
  • [Cites] Cancer Lett. 1994 Feb 28;77(1):25-32 [7512885.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):411-20 [8550786.001]
  • [Cites] J Natl Cancer Inst. 1996 May 1;88(9):601-6 [8609661.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Jun;28(6):619-37 [8673727.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1242-7 [8883411.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12181-8 [9115291.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25602-7 [9325280.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):283-93 [9516082.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):103-9 [9815544.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):624-8 [9842972.001]
  • [Cites] Endocrinology. 1999 Mar;140(3):1319-28 [10067859.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R119-29 [15642160.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):2-19 [15668470.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5015-9 [15958542.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):593-605 [16728585.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • (PMID = 17210081.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA064277; United States / NCI NIH HHS / CA / R01 CA090899; United States / NCI NIH HHS / CA / R01CA64277; United States / NCI NIH HHS / CA / R01CA90899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1851392
  •  go-up   go-down


29. Sharma A, Bandari R, Gilbert D, Sharma AK: Benign and malignant breast disease presenting to Bhaktapur Cancer Hospital. Kathmandu Univ Med J (KUMJ); 2005 Oct-Dec;3(4):384-7
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant breast disease presenting to Bhaktapur Cancer Hospital.
  • OBJECTIVE: In the absence of formal breast screening services in Nepal, patients must self present upon developing symptoms relating to the breast.
  • Clinical examination and diagnostic tests are then used to differentiate benign and malignant conditions.
  • METHOD: Here we present the clinico-pathological diagnoses of patients presenting to Bhaktapur Cancer Hospital with breast related complaints within a six month period, and report upon their subsequent management.
  • RESULTS: 727 patients presented with breast related complaints, of whom 34 were diagnosed with breast cancer.
  • CONCLUSION: As the incidence of breast cancer in Nepal is likely to be under-reported and more than likely rising, patient awareness campaigns are underway in order to facilitate the earlier diagnosis of malignant disease and thus beneficially influence treatment outcomes.
  • To this end the need for the development of dedicated breast services is highlighted.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449841.001).
  • [ISSN] 1812-2027
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


30. Moriya T, Kanomata N, Kozuka Y, Fukumoto M, Iwachido N, Hata S, Takahashi Y, Miura H, Ishida K, Watanabe M: Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions. Breast Cancer; 2009;16(3):173-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions.
  • Immunohistochemistry (IHC) is routinely performed during pathology practice for various breast lesions.
  • Hormone receptor and HER2 analysis for primary breast carcinoma and cytokeratin staining for sentinel lymph nodes analysis are widely conducted.
  • This manuscript will present three useful examples of IHC for making differential diagnosis between benign and malignant lesions.
  • Many cases with such morphology mimic benign papillomas, but expression of neuroendocrine markers may lead to the correct diagnosis.
  • Case 3 is a benign complex sclerosing lesion, with recognition of a pseudoinvasive process by myoepithelial markers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Immunohistochemistry / methods
  • [MeSH-minor] Adult. Breast Diseases / diagnosis. Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Clinical Laboratory Techniques. Diagnosis, Differential. Female. Humans. Middle Aged. Myoepithelioma / diagnosis. Myoepithelioma / metabolism. Myoepithelioma / pathology. Papilloma, Intraductal / diagnosis. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475479.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Zanetti-Dällenbach RA, Schmid S, Wight E, Holzgreve W, Ladewing A, Hahn S, Zhong XY: Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers; 2007 Apr-Jun;22(2):95-9
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of circulating cell-free serum DNA in benign and malignant breast lesions.
  • PURPOSES OF THE STUDY: We analyzed circulating cell-free DNA in the serum of patients with benign and malignant breast disease and in healthy individuals to determine its diagnostic value.
  • BASIC PROCEDURES: Serum samples were obtained from 50 healthy individuals, 33 patients with malignant breast disease and 32 patients with benign breast disease.
  • Tissue samples from patients with malignant and benign breast lesions were histopathologically examined.
  • MAIN FINDINGS: The mean levels of circulating cell-free DNA in serum samples were 41,149 genome equivalents (GE)/mL in patients with malignant disease, 30,826 GE/mL in patients with benign disease, and 13,267 GE/mL in healthy individuals.
  • Healthy individuals had significantly lower levels of cell-free DNA than patients with malignant or benign breast disease (p=0.001, p=0.031).
  • No significant difference was observed between malignant and benign disease.
  • PRINCIPAL CONCLUSION: Our results suggest that levels of circulating cell-free DNA in serum could have diagnostic value to discriminate between healthy individuals and patients with breast lesions but not between patients with malignant and benign breast lesions.
  • [MeSH-major] Breast Diseases / blood. Breast Neoplasms / blood. DNA / blood. DNA, Neoplasm / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549664.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


32. Nesaretnam K, Gomez PA, Selvaduray KR, Razak GA: Tocotrienol levels in adipose tissue of benign and malignant breast lumps in patients in Malaysia. Asia Pac J Clin Nutr; 2007;16(3):498-504
Hazardous Substances Data Bank. Palm oil (from fruit) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tocotrienol levels in adipose tissue of benign and malignant breast lumps in patients in Malaysia.
  • Data on dietary exposure to vitamin E by plasma or adipose tissue concentrations of alpha-tocopherol (alpha-T) in observational studies have failed to provide consistent support for the idea that alpha-T provides women with any protection from breast cancer.
  • In contrast, studies indicate that alpha, gamma, and delta-tocotrienols but not alpha-T have potent anti-proliferative effects in human breast cancer cells.
  • Our aim was to investigate whether there was a difference in tocopherol and tocotrienol concentrations in malignant and benign adipose tissue, in a Malaysian population consuming predominantly a palm oil diet.
  • The study was undertaken using fatty acid levels in breast adipose tissue as a biomarker of qualitative dietary intake of fatty acids.
  • The major fatty acids in breast adipose tissue of patients (benign and malignant) were oleic acid (45-46%), palmitic (28-29%) and linoleic (11-12%).
  • There was a significant difference (p=0.006) in the total tocotrienol levels between malignant (13.7 +/- 6.0 microg/g) and benign (20+/-6.0 microg/g) adipose tissue samples.
  • The higher adipose tissue concentrations of tocotrienols in benign patients provide support for the idea that tocotrienols may provide protection against breast cancer.
  • [MeSH-major] Adipose Tissue / chemistry. Antioxidants / analysis. Breast Neoplasms / metabolism. Tocopherols / analysis. Tocotrienols / analysis
  • [MeSH-minor] Breast / chemistry. Breast Diseases / metabolism. Dietary Fats, Unsaturated / administration & dosage. Female. Humans. Malaysia. Nutritional Status. Plant Oils. Vitamin E / analysis

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704032.001).
  • [ISSN] 0964-7058
  • [Journal-full-title] Asia Pacific journal of clinical nutrition
  • [ISO-abbreviation] Asia Pac J Clin Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Dietary Fats, Unsaturated; 0 / Plant Oils; 0 / Tocotrienols; 1406-18-4 / Vitamin E; 1406-66-2 / Tocopherols; 8002-75-3 / palm oil
  •  go-up   go-down


33. Siddiqui MK, Anand M, Mehrotra PK, Sarangi R, Mathur N: Biomonitoring of organochlorines in women with benign and malignant breast disease. Environ Res; 2005 Jun;98(2):250-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomonitoring of organochlorines in women with benign and malignant breast disease.
  • Established risk factors for breast cancer explain breast cancer risk only partially.
  • A hospital-based case-control study, the first from India, was conducted among 50 women undergoing surgery for breast disease to examine the association between organochlorine exposure and breast cancer risk.
  • Blood, tumor, and surrounding adipose tissue of the breast were collected from the subjects with benign (control) and malignant breast (study) lesions and analyzed to determine organochlorine insecticides using a gas-liquid chromatograph equipped with an electron capture detector.
  • The level of total HCH (alpha-HCH was significantly different, P<0.05) was higher in the breast adipose tissue of the study group, whereas total DDT was higher in the breast adipose tissue of the control group.
  • The distribution of known confounders of breast cancer including age, body mass index, age at menarche and menopause, duration of breast feeding, and family history related to breast disease did not differ significantly between benign and malignant groups.
  • This pilot study with limited statistical power does not support a positive association between exposure to organochlorines and risk of breast cancer but paves the way for a larger Indian study with greater statistical power encompassing different regions of the country to enable statistically sound conclusions.
  • [MeSH-major] Breast Neoplasms / etiology. Environmental Monitoring. Environmental Pollutants / pharmacokinetics. Hydrocarbons, Chlorinated / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820732.001).
  • [ISSN] 0013-9351
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated
  •  go-up   go-down


34. Xu H, Rao M, Varghese T, Sommer A, Baker S, Hall TJ, Sisney GA, Burnside ES: Axial-shear strain imaging for differentiating benign and malignant breast masses. Ultrasound Med Biol; 2010 Nov;36(11):1813-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axial-shear strain imaging for differentiating benign and malignant breast masses.
  • Axial strain imaging has been utilized for the characterization of breast masses for over a decade; however, another important feature namely the shear strain distribution around breast masses has only recently been used.
  • In this article, we examine the feasibility of utilizing in vivo axial-shear strain imaging for differentiating benign from malignant breast masses.
  • Radio-frequency data was acquired using a VFX 13-5 linear array transducer on 41 patients using a Siemens SONOLINE Antares real-time clinical scanner at the University of Wisconsin Breast Cancer Center.
  • Axial-shear strain areas normalized to the lesion size, applied strain and lesion strain contrast was utilized as a feature for differentiating benign from malignant masses.
  • The normalized axial-shear strain area feature estimated on eight patients with malignant tumors and 33 patients with fibroadenomas was utilized to demonstrate its potential for lesion differentiation.
  • Our results indicate that the normalized axial-shear strain area is significantly larger for malignant tumors compared with benign masses such as fibroadenomas.
  • A scatter plot of the normalized area feature demonstrates the feasibility of developing a linear classifier to differentiate benign from malignant masses.
  • The area under the receiver operator characteristic curve utilizing the normalized axial-shear strain area feature was 0.996, demonstrating the potential of this feature to noninvasively differentiate between benign and malignant breast masses.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
  • [Cites] Radiology. 1999 Dec;213(3):889-94 [10580971.001]
  • [Cites] Eur J Radiol. 2011 Mar;77(3):450-6 [19773141.001]
  • [Cites] Ultrasonics. 2000 Mar;38(1-8):400-4 [10829696.001]
  • [Cites] Ultrasound Med Biol. 2001 Nov;27(11):1461-9 [11750744.001]
  • [Cites] Radiographics. 2002 Mar-Apr;22(2):269-80; discussion 280-1 [11896217.001]
  • [Cites] Radiology. 2002 Oct;225(1):165-75 [12355001.001]
  • [Cites] Ultrasound Med Biol. 2003 Mar;29(3):427-35 [12706194.001]
  • [Cites] Ultrasound Med Biol. 2003 Oct;29(10):1387-96 [14597335.001]
  • [Cites] Radiologe. 2003 Oct;43(10):850-5 [14605701.001]
  • [Cites] Ultrasound Obstet Gynecol. 2004 Feb;23(2):188-93 [14770402.001]
  • [Cites] AJR Am J Roentgenol. 1983 Feb;140(2):369-75 [6600356.001]
  • [Cites] J Rehabil Res Dev. 1987 Spring;24(2):1-8 [3295197.001]
  • [Cites] Ultrasound Med Biol. 1990;16(3):241-6 [2194336.001]
  • [Cites] Ultrason Imaging. 1991 Apr;13(2):111-34 [1858217.001]
  • [Cites] AJR Am J Roentgenol. 1993 Feb;160(2):263-5 [8424330.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] Ultrasound Med Biol. 1995;21(6):745-51 [8571462.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1619-26 [8826919.001]
  • [Cites] Ultrasound Med Biol. 1995;21(9):1153-62 [8849830.001]
  • [Cites] Radiology. 1997 Jan;202(1):79-86 [8988195.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):109-14 [9423610.001]
  • [Cites] Ultrason Imaging. 1997 Jul;19(3):195-208 [9447668.001]
  • [Cites] Ultrasound Med Biol. 1998 Oct;24(8):1183-99 [9833588.001]
  • [Cites] Ultrasound Med Biol. 1999 Jan;25(1):75-87 [10048804.001]
  • [Cites] Proc Inst Mech Eng H. 1999;213(3):203-33 [10420776.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):449-62 [10430253.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Dec;23(12):1479-89 [15575406.001]
  • [Cites] J Ultrasound Med. 2005 Feb;24(2):161-7 [15661946.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1260-5 [15788607.001]
  • [Cites] AJR Am J Roentgenol. 2005 Oct;185(4):952-9 [16177414.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8469-76 [16293877.001]
  • [Cites] Phys Med Biol. 2005 Dec 21;50(24):5983-95 [16333168.001]
  • [Cites] Radiology. 2006 Feb;238(2):425-37 [16436810.001]
  • [Cites] Radiology. 2006 Aug;240(2):357-68 [16864666.001]
  • [Cites] J Ultrasound Med. 2007 Jan;26(1):47-53 [17182708.001]
  • [Cites] Ultrasound Med Biol. 2007 Jan;33(1):57-66 [17189047.001]
  • [Cites] Phys Med Biol. 2007 Jan 21;52(2):389-401 [17202622.001]
  • [Cites] Phys Med Biol. 2007 May 7;52(9):2615-33 [17440256.001]
  • [Cites] Radiology. 2007 Nov;245(2):401-10 [17940302.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Phys Med Biol. 2008 Sep 7;53(17):4809-23 [18701768.001]
  • [Cites] Ultrasound Med Biol. 2008 Sep;34(9):1373-86 [18395961.001]
  • [Cites] Bosn J Basic Med Sci. 2009 May;9(2):131-6 [19485945.001]
  • [Cites] Ultrasound Med Biol. 2009 Nov;35(11):1794-802 [19767139.001]
  • [Cites] Magn Reson Med. 2009 Dec;62(6):1457-65 [19859936.001]
  • [Cites] J Ultrasound Med. 2010 Jan;29(1):1-7 [20040770.001]
  • [Cites] Acta Radiol. 2010 Feb;51(1):9-14 [19929254.001]
  • [Cites] Eur Radiol. 2010 Feb;20(2):318-25 [19727753.001]
  • [ErratumIn] Ultrasound Med Biol. 2011 Oct;37(10):1743
  • (PMID = 20800948.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100373; United States / NCI NIH HHS / CA / R01CA112192-S103; United States / NIBIB NIH HHS / EB / R21 EB003853; United States / NCI NIH HHS / CA / R01CA100373; United States / NCI NIH HHS / CA / R01 CA111289; United States / NCI NIH HHS / CA / R01 CA112192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS223657; NLM/ PMC3033738
  •  go-up   go-down


35. Granowitz EV, Tonomura N, Benson RM, Katz DM, Band V, Makari-Judson GP, Osborne BA: Hyperbaric oxygen inhibits benign and malignant human mammary epithelial cell proliferation. Anticancer Res; 2005 Nov-Dec;25(6B):3833-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperbaric oxygen inhibits benign and malignant human mammary epithelial cell proliferation.
  • CONCLUSION: HBO inhibits benign and malignant mammary epithelial cell proliferation, but does not enhance cell death.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Hyperbaric Oxygenation. Mammary Glands, Human / drug effects. Oxygen / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16312043.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-02188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


36. Gupta S, Markey MK: Correspondence in texture features between two mammographic views. Med Phys; 2005 Jun;32(6Part1):1598-1606

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computer-aided diagnosis algorithms have been investigated for assisting in the detection and diagnosis of breast lesions in digitized/digital mammograms.
  • The purpose of this study was to investigate the correspondence in Haralick's texture features between the MLO and CC mammographic views of breast lesions.
  • Features were ranked on the basis of correlation values and the two-view correlation of features for subgroups of data including masses versus calcification and benign versus malignant lesions were compared.
  • Similarly, texture features from the two views were less strongly correlated for benign lesions than for malignant lesions.
  • The results suggest that the inclusion of texture features from multiple mammographic views in a CADx algorithm may impact the accuracy of diagnosis of calcification lesions and benign lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28513952.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computer aided diagnosis / Databases / Digital mammography / Entropy / Film mammography / General statistical methods / Image scanners / Mammography / Medical imaging / Radiologists / breast neoplasms / cancer / computer assisted / diagnosis / image processing / mammography / medical image processing / statistical analysis / tumours
  •  go-up   go-down


37. Kuo SJ, Hsiao YH, Huang YL, Chen DR: Classification of benign and malignant breast tumors using neural networks and three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynecol; 2008 Jul;32(1):97-102
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of benign and malignant breast tumors using neural networks and three-dimensional power Doppler ultrasound.
  • OBJECTIVES: To evaluate the use of three-dimensional (3D) power Doppler ultrasound in the differential diagnosis of solid breast tumors using a neural network model as a classifier.
  • METHODS: Data from 102 benign and 93 malignant breast tumor images that had pathological confirmation were collected consecutively from January 2003 to February 2004.
  • These data were applied to a multilayer perception (MLP) neural network model and we evaluated the model as a classifier to assess the capability of 3D power Doppler sonography to differentiate between benign and malignant solid breast tumors.
  • CONCLUSIONS: 3D power Doppler ultrasound may serve as a useful tool in distinguishing between benign and malignant breast tumors, and its capability may be increased by using a MLP neural network model as a classifier.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted. Imaging, Three-Dimensional. Ultrasonography, Doppler, Color / methods. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521971.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Yitta S, Singer CI, Toth HB, Mercado CL: Image presentation. Sonographic appearances of benign and malignant male breast disease with mammographic and pathologic correlation. J Ultrasound Med; 2010 Jun;29(6):931-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image presentation. Sonographic appearances of benign and malignant male breast disease with mammographic and pathologic correlation.
  • OBJECTIVE: Imaging of the male breast is most often performed for the evaluation of a clinical abnormality such as breast enlargement or tenderness, a palpable mass, nipple skin changes, or nipple discharge.
  • Most breast lesions encountered in men are benign.
  • Malignant breast lesions are less frequent; breast cancer accounts for less than 1% of all male cancers in the United States.
  • The initial imaging evaluation of a finding in the male breast is performed with mammography.
  • The objective of this article is to provide readers with a thorough review of the sonographic appearances of benign and malignant male breast disease.
  • METHODS: We reviewed our institution's case database to identify male patients who underwent mammography, sonography, and subsequent biopsy of a breast lesion.
  • RESULTS: A spectrum of benign and malignant male breast disease is presented with corresponding sonographic, mammographic, and pathologic imaging.
  • CONCLUSIONS: Most studies in the literature have reported on the mammographic and sonographic imaging features of primary breast carcinoma in men.
  • However, very little has been reported on the sonographic appearance of benign and malignant male breast conditions.
  • Recognition and correct identification of pathologic male breast entities on sonography is essential to determine appropriate management recommendations and avoid unnecessary biopsies.
  • [MeSH-major] Breast Neoplasms, Male / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Biopsy. Breast Diseases / pathology. Breast Diseases / radiography. Breast Diseases / ultrasonography. Diagnosis, Differential. Humans. Male. Mammography. Risk Factors

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20498468.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


39. Tsui PH, Liao YY, Chang CC, Kuo WH, Chang KJ, Yeh CK: Classification of benign and malignant breast tumors by 2-d analysis based on contour description and scatterer characterization. IEEE Trans Med Imaging; 2010 Feb;29(2):513-22
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of benign and malignant breast tumors by 2-d analysis based on contour description and scatterer characterization.
  • Ultrasound B-mode scanning based on the echo intensity has become an important clinical tool for routine breast screening.
  • The efficacy of the Nakagami parametric image based on the distribution of the backscattered signals for quantifying properties of breast tissue was recently evaluated.
  • The B-mode and Nakagami images reflect different physical characteristic of breast tumors: the former describes the contour features, and the latter reflects the scatterer arrangement inside a tumor.
  • The functional complementation of these two images encouraged us to propose a novel method of 2-D analysis based on describing the contour using the B-mode image and the scatterer properties using the Nakagami image, which may provide useful clues for classifying benign and malignant tumors.
  • To validate this concept, raw data were acquired from 60 clinical cases, and five contour feature parameters (tumor circularity, standard deviation of the normalized radial length, area ratio, roughness index, and standard deviation of the shortest distance) and the Nakagami parameters of benign and malignant tumors were calculated.
  • The clinical results demonstrated the presence of a tradeoff between the sensitivity and specificity when either using a single parameter or combining two contour parameters to discriminate between benign and malignant cases.
  • However, combining the contour parameters and the Nakagami parameter produces sensitivity and specificity that simultaneously exceed 80%, which means that the functional complementation from the B-scan and the Nakagami image indeed enhances the performance in diagnosing breast tumors.
  • [MeSH-major] Breast Neoplasms / classification. Image Interpretation, Computer-Assisted / methods. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20129851.001).
  • [ISSN] 1558-254X
  • [Journal-full-title] IEEE transactions on medical imaging
  • [ISO-abbreviation] IEEE Trans Med Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Hsiao YH, Huang YL, Kuo SJ, Liang WM, Chen ST, Chen DR: Characterization of benign and malignant solid breast masses in harmonic 3D power Doppler imaging. Eur J Radiol; 2009 Jul;71(1):89-95
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses in harmonic 3D power Doppler imaging.
  • PURPOSE: The authors assessed the characteristics of benign and malignant solid breast tumors in harmonic three-dimensional (3D) power Doppler imaging and proposed decision models to classify benign and malignant breast tumors.
  • MATERIALS AND METHODS: A total of 86 malignant and 97 benign harmonic 3D power Doppler US images were analyzed.
  • Histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), were calculated for the intra-tumor and for shells with an outside thickness of 3mm surrounding the breast tumors.
  • RESULTS: The results revealed that the choice of decision model comprised the parameters of patient age, intra-tumor VI, and tumor volume to classify benign and malignant breast tumors.
  • The parameter intra-tumor VI was the choice for all of the histogram indices in differentiating between malignant and benign lesions.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Imaging, Three-Dimensional / methods. Ultrasonography, Doppler / methods. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479868.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


41. Steppan I, Reimer D, Müller-Holzner E, Marth C, Aigner F, Frauscher F, Frede T, Zeimet AG: Breast cancer in women: evaluation of benign and malignant axillary lymph nodes with contrast-enhanced ultrasound. Ultraschall Med; 2010 Feb;31(1):63-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in women: evaluation of benign and malignant axillary lymph nodes with contrast-enhanced ultrasound.
  • PURPOSE: We assessed the value of contrast-enhanced US for differentiating between benign and malignant axillary lymph nodes in breast cancer.
  • MATERIALS AND METHODS: A total of 120 axillary lymph nodes in 92 patients with breast cancer were studied.
  • Of all 120 axillary lymph nodes studied, 80 (67 %) were malignant and 40 (33 %) were benign according to pathological examination.
  • The total number of vessels in baseline US did not increase between benign and malignant lymph nodes (3.3 +/- 2.2 vs. 5.4 +/- 4.0; p > 0.05).
  • The total number of peripheral vessels was 0.5 +/- 0.8 for benign lymph nodes vs. 2.0 +/- 1.7 for malignant lymph nodes (p > 0.05).
  • Enhanced US studies showed enhancement in both benign and malignant lymph nodes after contrast administration with a significantly higher degree of enhancement in malignant lymph nodes (p < 0.01).
  • The total number of vessels was significantly higher in malignant lymph nodes after contrast administration (17.3 +/- 8.0 vs. 8.2 +/- 5.1, p < 0.01).
  • Malignant lymph nodes demonstrated longer contrast enhancement duration compared to benign lymph nodes.
  • CONCLUSION: This preliminary data shows that contrast-enhanced US can differentiate between benign and malignant lymph nodes in breast cancer.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Enhancement / methods. Lymph Nodes / ultrasonography. Lymphatic Metastasis / ultrasonography. Ultrasonography, Doppler, Color / methods. Ultrasonography, Mammary / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20094979.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng; ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


42. Karim BO, Ali SZ, Landolfi JA, Mann JF, Liu G, Christian A, Dicello JF, Rosenthal DL, Huso DL: Cytomorphologic differentiation of benign and malignant mammary tumors in fine needle aspirate specimens from irradiated female Sprague-Dawley rats. Vet Clin Pathol; 2008 Jun;37(2):229-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic differentiation of benign and malignant mammary tumors in fine needle aspirate specimens from irradiated female Sprague-Dawley rats.
  • BACKGROUND: Fine needle aspiration (FNA) offers a rapid and minimally invasive means to distinguish malignant from benign neoplasms.
  • However, few studies have been published regarding the cytopathology of mammary tumors in rats despite widespread use of the rat model for breast cancer formation and inhibition.
  • OBJECTIVE: The purpose of this study was to determine the diagnostic accuracy of FNA cytology and to develop distinguishing cytologic criteria for the diagnosis of radiation-induced benign and malignant mammary tumors in rats.
  • Cytologic and histologic diagnoses (benign vs malignant) were compared, and diagnostic accuracy was calculated using the histologic diagnosis as the criterion standard.
  • Cytomorphologic features were compared statistically between benign and malignant tumors, based on the histologic diagnosis.
  • Malignant tumors had significantly higher scores for all cytomorphologic features, and were significantly more likely to contain cell clusters and necrotic debris.
  • CONCLUSIONS: FNA is an accurate method for differentiating benign and malignant rat mammary tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533925.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K01RR021362; United States / PHS HHS / / RE00205; United States / NCRR NIH HHS / RR / RR00171
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


43. Aghaei M, Karami-Tehrani F, Salami S, Atri M: Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors. Arch Med Res; 2010 Jan;41(1):14-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors.
  • BACKGROUND AND AIMS: The present study was carried out to evaluate the activity of adenosine deaminase (ADA) and its isoenzymes ADA1 and ADA2 activities as a diagnostic tool in patients with benign and malignant breast disease.
  • METHODS: Total ADA, ADA1, and ADA2 activities of serum and tumor were analyzed using 58 subjects including 20 patients with benign breast disease (BBD), 34 patients with primary breast cancer, and 20 patients as normal control subjects.
  • Furthermore, the mean values for total ADA and ADA2 activities of patients with breast cancer were significantly higher than those of the benign group (p <0.005) and healthy subjects (p <0.0001).
  • CONCLUSIONS: Based on the present results, it is concluded that the assessment of total ADA and ADA2 activities may be used as a reliable test for differential diagnosis of benign and malignant breast disease.
  • [MeSH-major] Adenosine Deaminase / metabolism. Breast Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 IMSS. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20430249.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


44. Moon WK, Choi JW, Cho N, Park SH, Chang JM, Jang M, Kim KG: Computer-aided analysis of ultrasound elasticity images for classification of benign and malignant breast masses. AJR Am J Roentgenol; 2010 Dec;195(6):1460-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided analysis of ultrasound elasticity images for classification of benign and malignant breast masses.
  • OBJECTIVE: The purpose of this study was to evaluate computer-aided analysis of ultrasound elasticity images for the classification of benign and malignant breast tumors.
  • MATERIALS AND METHODS: Real-time ultrasound elastography of 140 women (mean age, 46 years; age range, 35-67 years) with nonpalpable breast masses (101 benign and 39 malignant lesions) was performed before needle biopsy.
  • CONCLUSION: Computer-aided analysis of ultrasound elasticity images has the potential to aid in the classification of benign and malignant breast tumors.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Elasticity Imaging Techniques / methods. Image Interpretation, Computer-Assisted / methods. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21098210.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Zhao Z, Li FL, Zhao LX, Su MG: [SPECT/CT fusion imaging for the diagnosis of benign and malignant lesions in bones]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Nov;39(6):1036-9
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [SPECT/CT fusion imaging for the diagnosis of benign and malignant lesions in bones].
  • OBJECTIVE: The aim of the study was to evaluate the value of the single photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging in the diagnosis of benign and malignant lesions in bones.
  • CONCLUSION: SPECT/CT can effectively differentiate benign and malignant bone lesions.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / secondary. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Middle Aged. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary. Sensitivity and Specificity. Technetium Tc 99m Medronate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253855.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


46. Floery D, Helbich TH, Riedl CC, Jaromi S, Weber M, Leodolter S, Fuchsjaeger MH: Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol; 2005 Jun;40(6):328-35
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience.
  • OBJECTIVES: The aim of this study was to characterize benign and malignant breast lesions with computed tomography-laser mammography (CTLM).
  • MATERIALS AND METHODS: In a prospective study, 100 female patients with 105 breast lesions classified as BIRADS IV to V at mammography underwent mammography, CTLM, and histologic verification at our institution.
  • RESULTS: Histologic analysis revealed 55 benign (52.4%) and 50 malignant (47.6%) breast lesions.
  • Increased absorption was observed significantly more often in malignant than in benign lesions (70.0% vs. 32.7%, P = 0.028).
  • Common morphologic characteristics of increased absorption were "volumes" (85.7% of malignant and 77.8% of benign lesions) with round shape (78.1% of malignant and 73.3% of benign lesions).
  • CONCLUSION: Our data indicate that CTLM, when used as an adjunct to mammography, may provide additional information to characterize benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / radiography. Breast Neoplasms / radiography. Lasers. Mammography / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905718.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Polat A: c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases. Pathol Res Pract; 2007;203(11):765-9
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases.
  • Columnar cell lesions (CCLs) of the breast are reported with increasing frequency.
  • The aim of the present study was to evaluate c-KIT expression in CCLs accompanying benign and malignant breast diseases.
  • A total of 65 patients (18 benign breast diseases, 8 ductal carcinomas in situ (DCI), and 39 invasive carcinomas) were included in the study. c-KIT was strongly expressed in normal breast epithelium (staining intensity; SI: 3 +/- 0.0), whereas a heterogeneous and cytoplasmic staining pattern was observed in CCLs accompanying both benign and malignant diseases. c-KIT expression was decreased, with increasing atypia in CCLs (SI in CCLs with/without atypia; 1.45 +/- 0.52/no case, 1.25 +/- 0.50/1.38 +/- 0.52, 0.77 +/- 0.73/1.21 +/- 0.42 accompanying benign breast disease, DCI and invasive carcinoma, respectively).
  • As there is a reduction in c-KIT expression with malignant transformation of breast epithelium, c-KIT is believed to play a role in breast carcinogenesis.
  • Furthermore, similar c-KIT expression patterns in CCLs accompanying malignant breast diseases suggest that at least some CCLs could reflect a premalignant status of breast carcinoma.
  • However, the significance of c-KIT expression in CCLs and its relationship to breast carcinogenesis should be evaluated in follow up studies investigating larger series.
  • [MeSH-major] Breast Diseases / metabolism. Breast Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931792.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


48. Hsiao YH, Huang YL, Liang WM, Lin C, Kuo SJ, Chen DR: Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging. Ultrasound Med Biol; 2009 Mar;35(3):353-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging.
  • The aim of this study was to compare the diagnostic performance of nonharmonic ultrasound (US) and tissue harmonic imaging (THI) using three-dimensional (3D) power Doppler sonographic technique to classify benign and malignant breast tumors by vascularization.
  • From January 2003 to February 2004, we evaluated 200 patients and one of lobular carcinoma in situ was excluded from the malignant category.
  • All subjects with one or more breast masses were studied with 3D power Doppler US nonharmonic and harmonic technologies.
  • A total of 97 benign and 86 pathologically proven malignant breast tumor images were analyzed.
  • Three histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), on both nonharmonic and harmonic images were calculated for the intratumor and for shells with an outside thickness of 3 mm surrounding the breast lesion.
  • A multilayer perception (MLP) neural network classifier used the vascularity indices to determine whether the breast tumors are benign or malignant.
  • ROC curve analysis used overall age, volume, VI, FI and VFI for both intratumor and shells with an outside thickness of 3 mm surrounding the breast lesions in nonharmonic US and THI.
  • In conclusion, the performance of 3D power Doppler US with respect to the characterization of solid breast masses as benign or malignant was not significantly improved with tissue harmonic imaging.
  • [MeSH-major] Breast Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041173.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Kukreti S, Cerussi AE, Tanamai W, Hsiang D, Tromberg BJ, Gratton E: Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy. Radiology; 2010 Jan;254(1):277-84
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy.
  • PURPOSE: To develop a near-infrared spectroscopic method to identify breast cancer biomarkers and to retrospectively determine if benign and malignant breast lesions could be distinguished by using this method.
  • By using self-referencing differential spectroscopy (SRDS) analysis, the existence of specific spectroscopic signatures of breast lesions on images acquired by using diffuse optical spectroscopy imaging in the wavelength range (650-1000 nm) was established.
  • There were 17 patients with benign breast tumors and 22 patients with malignant breast tumors.
  • RESULTS: Discrimination analysis helped separate malignant from benign tumors.
  • A total of 40 lesions (22 malignant and 18 benign) were analyzed.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):383-91 [10989610.001]
  • [Cites] Breast Cancer Res Treat. 2007 Sep;104(3):249-55 [17051424.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1016-22 [11308247.001]
  • [Cites] Magn Reson Med. 2001 Jun;45(6):994-1000 [11378876.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):45-54 [11678308.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):60-71 [11818013.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1197-203 [12189222.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1134-43 [14648561.001]
  • [Cites] Breast. 2003 Jun;12(3):179-82 [14659324.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):464-73 [15189083.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):541-52 [15189092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6468-73 [9177241.001]
  • [Cites] Radiology. 1998 Oct;209(1):269-75 [9769842.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):159-64 [10441019.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1737-46 [10470108.001]
  • [Cites] Radiology. 2004 Nov;233(2):424-31 [15516615.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2451-68 [15901948.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] J Lipid Res. 2005 Sep;46(9):1983-90 [15961785.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051503 [16292947.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):427-35 [16465174.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S302-5 [16507398.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):325-32 [16786567.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Expert Rev Med Devices. 2007 Jan;4(1):83-95 [17187474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):020509 [17477706.001]
  • [Cites] Radiology. 2001 Jan;218(1):261-6 [11152812.001]
  • (PMID = 20032159.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142989; United States / NCI NIH HHS / CA / U54 CA136400-01; None / None / / P41 RR001192-31; United States / NCI NIH HHS / CA / R01 CA142989-01; United States / NCRR NIH HHS / RR / P41 RR001192-31; United States / NIBIB NIH HHS / EB / R01 EB000559; United States / NCI NIH HHS / CA / U54 CA136400-02; United States / NCI NIH HHS / CA / U54 CA105480-05; United States / NCI NIH HHS / CA / U54 CA105480; United States / NCI NIH HHS / CA / U54 CA136400; United States / NCI NIH HHS / CA / R01 CA142989-02; United States / NCI NIH HHS / CA / P30-CA62203; United States / NCRR NIH HHS / RR / P41 RR003155; United States / NCRR NIH HHS / RR / P41 RR001192; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCRR NIH HHS / RR / P41-RR01192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2797652
  •  go-up   go-down


50. Sirotkovic-Skerlev M, Cacev T, Krizanac S, Kulić A, Pavelic K, Kapitanovic S: TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol; 2007 Aug;83(1):54-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions.
  • The multifunctional cytokine tumor necrosis factor alpha (TNF alpha) has an important role in the pathogenesis of inflammatory, autoimmune and malignant diseases.
  • The aim of our study was to investigate the frequency of three TNF alpha promoter polymorphisms (-1031, -308 and -238) in benign (fibrocystic changes) and malignant (invasive carcinoma) breast lesions.
  • Using "real-time" PCR SNP analysis these polymorphisms were determined in 76 patients with benign and 158 patients with malignant breast lesions.
  • The high expression genotypes at any of the three SNP polymorphisms were more frequent in invasive breast carcinoma (in 81 of 158 examined, 51.3%) than in fibrocystic changes (in 33 of 76 examined, 43.4%).
  • The combined frequency of high production genotypes (-1031 T/C and C/C, -308 G/A and A/A and -238 G/A and A/A) was higher in patients with invasive breast carcinoma than in those with fibrocystic changes.
  • Further studies on a larger group of patients are needed to evaluate the significance of potential differences in TNF alpha genotypes in different breast lesions.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Fibrocystic Breast Disease / genetics. Fibrocystic Breast Disease / pathology. Polymorphism, Genetic / genetics. Tumor Necrosis Factor-alpha / analysis. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Gene Expression Regulation. Genotype. Humans. Middle Aged. Neoplasm Invasiveness. Promoter Regions, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234183.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


51. Choe R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, Demichele A, Chance B, Arridge SR, Schweiger M, Culver JP, Schnall MD, Putt ME, Rosen MA, Yodh AG: Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt; 2009 Mar-Apr;14(2):024020
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography.
  • We have developed a novel parallel-plate diffuse optical tomography (DOT) system for three-dimensional in vivo imaging of human breast tumor based on large optical data sets.
  • Malignant cancers (N=41) showed statistically significant higher total hemoglobin, oxy-hemoglobin concentration, and scattering compared to normal tissue.
  • Furthermore, malignant lesions exhibited a twofold average increase in optical index.
  • The influence of core biopsy on DOT results was also explored; the difference between the malignant group measured before core biopsy and the group measured more than 1 week after core biopsy was not significant.
  • Benign tumors (N=10) did not exhibit statistical significance in the tumor-to-normal ratios of any parameter.
  • The data demonstrate that benign and malignant lesions can be distinguished by quantitative three-dimensional DOT.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Med Biol. 2007 Jun 21;52(12):3619-41 [17664563.001]
  • [Cites] J Surg Oncol. 2007 Nov 1;96(6):457-63 [17929256.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051902 [17994885.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051903 [17994886.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):9-22 [17468951.001]
  • [Cites] Med Phys. 2008 Feb;35(2):446-55 [18383664.001]
  • [Cites] Opt Express. 2008 Mar 31;16(7):5048-60 [18542605.001]
  • [Cites] Med Phys. 2008 Jun;35(6):2493-501 [18649482.001]
  • [Cites] Cancer Metastasis Rev. 2008 Dec;27(4):615-30 [18506398.001]
  • [Cites] Neoplasia. 2008 Oct;10(10):1028-40 [18813360.001]
  • [Cites] Q J Nucl Med. 2001 Sep;45(3):245-56 [11788817.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):72-9 [11818014.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):80-7 [11818015.001]
  • [Cites] Acad Radiol. 2002 Feb;9(2):186-94 [11918371.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):347-54 [12082551.001]
  • [Cites] Phys Med Biol. 2002 Aug 21;47(16):2847-61 [12222850.001]
  • [Cites] Appl Opt. 2003 Jan 1;42(1):135-45 [12518832.001]
  • [Cites] Med Phys. 2003 Feb;30(2):235-47 [12607841.001]
  • [Cites] Opt Lett. 2003 Mar 1;28(5):337-9 [12659436.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2767-72 [10706610.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):26-40 [10933066.001]
  • [Cites] Acad Radiol. 2000 Oct;7(10):783-5 [11048875.001]
  • [Cites] Clin Imaging. 2000 Mar-Apr;24(2):96-103 [11124482.001]
  • [Cites] Radiology. 2001 Jan;218(1):261-6 [11152812.001]
  • [Cites] Radiology. 2001 Apr;219(1):192-202 [11274556.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1152-60 [15568935.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Appl Opt. 2005 Apr 1;44(10):1898-904 [15813526.001]
  • [Cites] Appl Opt. 2005 Apr 10;44(11):2082-93 [15835357.001]
  • [Cites] Appl Opt. 2005 Apr 10;44(11):2140-53 [15835360.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1334-40 [11811833.001]
  • [Cites] Appl Opt. 2003 Jun 1;42(16):3117-28 [12790463.001]
  • [Cites] Appl Opt. 2003 Sep 1;42(25):5181-90 [12962399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12349-54 [14514888.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):379-88 [14670175.001]
  • [Cites] Opt Lett. 2003 Dec 1;28(23):2339-41 [14680175.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] Acad Radiol. 2004 Jan;11(1):53-60 [14746402.001]
  • [Cites] Br J Radiol. 1986 Dec;59(708):1209-18 [3801800.001]
  • [Cites] Br J Radiol. 1987 Sep;60(717):907-13 [3664185.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3316-22 [2040005.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] J Opt Soc Am A Opt Image Sci Vis. 1994 Oct;11(10):2727-41 [7931757.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 1;89(1):76-82 [8978410.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):501-6 [9016235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6468-73 [9177241.001]
  • [Cites] Radiology. 1997 Jul;204(1):131-5 [9205234.001]
  • [Cites] Ann N Y Acad Sci. 1998 Feb 9;838:171-93 [9511805.001]
  • [Cites] N Engl J Med. 1998 Apr 16;338(16):1089-96 [9545356.001]
  • [Cites] Q J Nucl Med. 1998 Mar;42(1):1-7 [9646639.001]
  • [Cites] J Natl Cancer Inst Monogr. 1997;(22):5-9 [9709267.001]
  • [Cites] Adv Exp Med Biol. 1998;454:591-602 [9889939.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1137-42 [15568933.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2429-49 [15901947.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2451-68 [15901948.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2469-88 [15901949.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2489-502 [15901950.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2503-17 [15901951.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024033 [15910106.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] Technol Cancer Res Treat. 2005 Oct;4(5):513-26 [16173822.001]
  • [Cites] Bioinformatics. 2005 Oct 15;21(20):3940-1 [16096348.001]
  • [Cites] Opt Lett. 2005 Nov 1;30(21):2915-7 [16279468.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051503 [16292947.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8828-33 [16731633.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] Opt Lett. 2007 Apr 15;32(8):933-5 [17375158.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Appl Opt. 2007 Jun 10;46(17):3628-38 [17514325.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1143-56 [17627478.001]
  • (PMID = 19405750.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR002305-24; United States / NCI NIH HHS / CA / U54CA105480; United States / NIBIB NIH HHS / EB / R01-EB002109; United States / NCI NIH HHS / CA / U54 CA105480-04; United States / NIBIB NIH HHS / EB / R01 EB002109-08; United States / NIBIB NIH HHS / EB / EB002109-12; United States / NIBIB NIH HHS / EB / R01 EB002109-09; United States / NCI NIH HHS / CA / U54 CA105480-05; United States / NCI NIH HHS / CA / R01 CA075124-06; United States / NCI NIH HHS / CA / U54 CA105480-02; United States / NIBIB NIH HHS / EB / R01 EB002109-10; United States / NCI NIH HHS / CA / CA126187-01A1; United States / NIBIB NIH HHS / EB / EB002109-09; United States / NCI NIH HHS / CA / K99-CA126187; United States / NCI NIH HHS / CA / U54 CA105480; United States / NCI NIH HHS / CA / CA075124-04; United States / NCI NIH HHS / CA / U54 CA105480-03; United States / NIBIB NIH HHS / EB / R01 EB002109-07; United States / NCRR NIH HHS / RR / P41-RR002305; United States / NCI NIH HHS / CA / R01-CA75124; United States / NIBIB NIH HHS / EB / EB002109-10; United States / NCI NIH HHS / CA / CA075124-05; United States / NIBIB NIH HHS / EB / EB002109-08; United States / NCI NIH HHS / CA / R01 CA075124-05; United States / NINDS NIH HHS / NS / R01 NS060653; United States / NIBIB NIH HHS / EB / R01 EB002109-12; United States / NCI NIH HHS / CA / K99 CA126187; United States / NCI NIH HHS / CA / U54 CA105480-01; United States / NCI NIH HHS / CA / CA075124-06; United States / NIBIB NIH HHS / EB / R01 EB002109-11; United States / NCRR NIH HHS / RR / P41 RR002305-24; United States / NCI NIH HHS / CA / K99 CA126187-01A1; United States / NCRR NIH HHS / RR / P41 RR002305; United States / NCI NIH HHS / CA / R01 CA075124-04; United States / NCI NIH HHS / CA / R01 CA075124; United States / NCRR NIH HHS / RR / P41 RR002305-25; United States / NIBIB NIH HHS / EB / EB002109-07; United States / NIBIB NIH HHS / EB / EB002109-11; United States / NIBIB NIH HHS / EB / R01 EB002109
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS129120; NLM/ PMC2782703
  •  go-up   go-down


52. Shahid R, Ghaffar A, Bhatti AM: Role of grey scale ultrasound in benign and malignant breast lesions. J Coll Physicians Surg Pak; 2005 Apr;15(4):193-5
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of grey scale ultrasound in benign and malignant breast lesions.
  • OBJECTIVE: To evaluate the sensitivity and specificity of ultrasound in diagnosis of benign and malignant disease in correlation with histopathological findings.
  • PATIENTS AND METHODS: Adult female patients presenting with breast lump were included.
  • RESULTS: Eighty-five female patients with positive clinical findings were differentiated into benign (n =45, 52.9%), intermediate (n =15, 17.6%) and malignant (n =25, 29.4%), by ultrasound examination.
  • Only one (2.2%) benign lesion was found malignant on histopathology, 8 (32%) cases of malignant group were benign on histopathology.
  • The sensitivity of ultrasound for malignant lesion was 95.24% and specificity was 68.75% for a benign lesion.
  • CONCLUSION: Ultrasound of breast is very useful in evaluating breast lumps.
  • [MeSH-major] Breast Diseases / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibroadenoma / ultrasonography. Humans. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15857587.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


53. Kurimoto M, Fukuda I, Hizuka N, Takano K: The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J; 2008 Mar;55(1):67-71
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of benign and malignant tumors in patients with acromegaly at a single institute.
  • It has been reported that patients with acromegaly may have an increased risk of developing several types of cancers, such as colorectal, breast and prostate tumors.
  • In this study, we determined the prevalence of benign and malignant neoplasms in patients with acromegaly.
  • Colon cancer was found in 10 patients, thyroid cancer in 5, breast cancer in 4 and gastric cancer in 2.
  • Of the benign tumors, multinodular goiter and colonic, gastric and gallbladder polyps were observed in 57% (47/83), 40% (35/87), 23% (10/43), and 14% (11/77) [corrected] of the patients, respectively.
  • [MeSH-major] Acromegaly / complications. Acromegaly / epidemiology. Neoplasms / complications. Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / complications. Breast Neoplasms / epidemiology. Carcinoma / complications. Carcinoma / epidemiology. Colonic Neoplasms / complications. Colonic Neoplasms / epidemiology. Female. Humans. Incidence. Leiomyosarcoma / complications. Leiomyosarcoma / epidemiology. Male. Middle Aged. Prevalence. Retrospective Studies. Stomach Neoplasms / complications. Stomach Neoplasms / epidemiology. Thyroid Diseases / complications. Thyroid Diseases / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr J. 2008 Aug;55(4):786
  • (PMID = 18202526.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


54. Tsui PH, Yeh CK, Liao YY, Chang CC, Kuo WH, Chang KJ, Chen CN: Ultrasonic Nakagami imaging: a strategy to visualize the scatterer properties of benign and malignant breast tumors. Ultrasound Med Biol; 2010 Feb;36(2):209-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonic Nakagami imaging: a strategy to visualize the scatterer properties of benign and malignant breast tumors.
  • Previous studies have demonstrated the usefulness of the Nakagami parameter in characterizing breast tumors by ultrasound.
  • However, physicians or radiologists may need imaging tools in a clinical setting to visually identify the properties of breast tumors.
  • This study proposed the ultrasonic Nakagami image to visualize the scatterer properties of breast tumors and then explored its clinical performance in classifying benign and malignant tumors.
  • Raw data of ultrasonic backscattered signals were collected from 100 patients (50 benign and 50 malignant cases) using a commercial ultrasound scanner with a 7.5 MHz linear array transducer.
  • The backscattered signals were used to form the B-scan and the Nakagami images of breast tumors.
  • The results showed that the Nakagami image shadings in benign tumors were different from those in malignant cases.
  • The average Nakagami parameters for benign and malignant tumors were 0.69 +/- 0.12 and 0.55 +/- 0.12, respectively.
  • This means that the backscattered signals received from malignant tumors tend to be more pre-Rayleigh distributed than those from benign tumors, corresponding to a more complex scatterer arrangement or composition.
  • The results showed that the Nakagami image is useful to distinguishing between benign and malignant breast tumors.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / ultrasonography. Neoplasm Metastasis / ultrasonography. Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20018436.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


55. Zhang J, Jiang YX, Dai Q, Sun Q, Lü K, Tan L, Gao P: [Application of real-time gray-scale contrast-enhanced ultrasound in the diagnosis of benign and malignant breast lesions]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Feb;30(1):49-53
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of real-time gray-scale contrast-enhanced ultrasound in the diagnosis of benign and malignant breast lesions].
  • OBJECTIVE: To observe the patterns of benign and malignant breast lesions using real-time gray-scale contrast-enhanced ultrasound and assess its value in the differential diagnosis of begign and malignant breast tumors.
  • METHODS: Totally 116 breast lesions (benignity n = 63; malignancy n = 53) underwent real-time gray-scale contrast-enhanced ultrasound.
  • RESULTS: Contrast-enhanced sonographic patterns were significantly different between benign and malignant breast lesions.
  • Most malignant lesions were non-centripetally, incompletely, and inhomogeneously enhanced.
  • After having been injected with the microbubble contrast medium, the boundary of the lesions became unclear, and the radial enhancement around lesion were mainly seen in the malignant lesions.
  • CONCLUSION: The patterns of real-time gray-scale contrast-enhanced ultrasound are remarkably different between malignant and benign breast lesions, showing promising values for its clinical application.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Contrast Media

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361053.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


56. Barnard S, Leen E, Cooke T, Angerson W: A contrast-enhanced ultrasound study of benign and malignant breast tissue. S Afr Med J; 2008 May;98(5):386-91
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A contrast-enhanced ultrasound study of benign and malignant breast tissue.
  • OBJECTIVE: To determine the diagnostic value of haemodynamic contrast-enhanced ultrasound assessment in benign and malignant breast tissue, using histological examination as the reference standard.
  • METHODS: An HDI 5000 Phillips ultrasound scanner with microvascular imaging software and 2.5 ml SonoVue (Bracco spa, Milan) contrast was used to scan 50 consecutive patients (32 malignant and 18 benign, 49 with histologically confirmed breast lesions).
  • Time-intensity curves of the regions of interest (ROI) placed over the lesional and normal breast tissues were acquired using QLAB software.
  • The area under the curve (AUC), time to peak (TTP), in-flow gradient (IFG) and peak enhancement (PE) were determined in a standardised manner for each focal breast lesion and the control/normal breast.
  • IFG and AUC in the periphery, and PE and AUC in the centre of the lesions, differed significantly between malignant and benign tumours.
  • In a logistical regression model, AUC in the periphery and the ratio of PE at the tumour centre to that of normal breast were independently predictive of malignancy (p < 0.001), achieving a diagnostic sensitivity of 97% and a specificity of 80% in the 41 tumours in which central vessels could be distinguished.
  • CONCLUSION: Haemodynamic contrast-enhanced ultrasound assessment can be used to distinguish between benign and malignant breast lesions.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Carcinoma / ultrasonography. Contrast Media. Fibrocystic Breast Disease / ultrasonography. Phospholipids. Sulfur Hexafluoride. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637311.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


57. Muramatsu C, Schmidt RA, Shiraishi J, Li Q, Doi K: Presentation of similar images as a reference for distinction between benign and malignant masses on mammograms: analysis of initial observer study. J Digit Imaging; 2010 Oct;23(5):592-602
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation of similar images as a reference for distinction between benign and malignant masses on mammograms: analysis of initial observer study.
  • The effect of the presentation of similar images for distinction between benign and malignant masses on mammograms was evaluated in the observer performance study.
  • We selected 50 benign and 50 malignant masses by a stratified randomization method.
  • Radiologists were shown images with unknown masses and asked to provide their confidence level that the lesions were malignant before and after the presentation of the similar images.
  • Eleven observers, including three attending breast radiologists, three breast imaging fellows, and five residents, participated.
  • From a detailed analysis of the reasons for these detrimental effects, we found that the similar images would not be useful for diagnosis of rare and very difficult cases, i.e., benign-looking malignant and malignant-looking benign cases.
  • [MeSH-major] Breast Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Radiol. 1992 Sep;27(9):723-31 [1399456.001]
  • [Cites] Radiology. 1989 Aug;172(2):487-93 [2664871.001]
  • [Cites] Acad Radiol. 1999 Jan;6(1):22-33 [9891149.001]
  • [Cites] Radiology. 1999 Sep;212(3):817-27 [10478252.001]
  • [Cites] Radiology. 2005 Jun;235(3):775-90 [15914475.001]
  • [Cites] Br J Radiol. 2005;78 Spec No 1:S3-S19 [15917443.001]
  • [Cites] Med Phys. 2005 Jul;32(7):2295-304 [16121585.001]
  • [Cites] Med Phys. 2006 Jan;33(1):111-7 [16485416.001]
  • [Cites] Radiology. 2006 Aug;240(2):357-68 [16864666.001]
  • [Cites] Comput Med Imaging Graph. 2007 Jun-Jul;31(4-5):198-211 [17349778.001]
  • [Cites] Acad Radiol. 2008 Jul;15(7):887-94 [18572125.001]
  • [Cites] Acad Radiol. 2009 Apr;16(4):443-9 [19268856.001]
  • [Cites] Acad Radiol. 2000 Jun;7(6):395-405 [10845398.001]
  • [Cites] Radiology. 2002 Aug;224(2):560-8 [12147857.001]
  • [Cites] Radiology. 2003 Jul;228(1):265-70 [12832587.001]
  • [Cites] Med Phys. 2003 Oct;30(10):2584-93 [14596294.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1260-1; author reply 1261 [15316065.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Oct;23(10):1233-44 [15493691.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1007-11 [6821864.001]
  • [Cites] Radiology. 1988 May;167(2):353-8 [3282256.001]
  • [Cites] Radiology. 1988 Dec;169(3):621-6 [2847231.001]
  • [Cites] Radiology. 1996 Aug;200(2):357-60 [8685325.001]
  • (PMID = 20054606.001).
  • [ISSN] 1618-727X
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3046675
  •  go-up   go-down


58. Cîmpean AM, Raica M, Nariţa D: Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast. Rom J Morphol Embryol; 2005;46(2):123-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.
  • PURPOSE: Our aim was to investigate the distribution of CD34 and smooth muscle cell actin positive myofibroblasts in the stroma of the normal mammary gland, benign and malignant tumors.
  • METHODS: Our study included 112 female patients with suspect breast masses obtained by surgery or biopsy.
  • RESULTS: We have found normal breast tissue, sclerosing adenosis, fibroadenomas, fibrocystic diseases, phyllodes tumor, DCIS, ductal invasive, lobular, squamous, medullary, mucinous, and papillary carcinomas.
  • We also found apocrine metaplasia, florid ductal hyperplasia, atypical hyperplasia, papilloma and LCIS associated with the malignant tumors.
  • All the normal breast tissues and most of benign lesions were positive for CD34 and negative for SMA.
  • CONCLUSIONS: Although there were some exceptions especially when one of the two markers was interpreted separately and in some cases associated with sclerotic stroma, we conclude that the combined expression of CD34 and a-SMA is of potential diagnostic value in the distinction between benign and malignant tumors in some difficult cases.
  • [MeSH-major] Actins / analysis. Antigens, CD34 / analysis. Breast Neoplasms / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Biopsy. Carcinoma, Ductal / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Smad Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286998.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Smad Proteins
  •  go-up   go-down


59. Partridge SC, Mullins CD, Kurland BF, Allain MD, DeMartini WB, Eby PR, Lehman CD: Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol; 2010 Jun;194(6):1664-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size.
  • OBJECTIVE: The purpose of this study was to determine whether lesion type and size affect discrimination of benign and malignant breast lesions with diffusion-weighted MRI.
  • MATERIALS AND METHODS: This study included 91 women with 116 breast lesions identified with dynamic contrast-enhanced MRI.
  • Diffusion-weighted images were acquired during clinical breast MRI at b values of 0 and 600 s/mm(2).
  • Differences in the apparent diffusion coefficients (ADCs) of benign and malignant lesions were compared by lesion type (mass or nonmasslike enhancement) and size (<or= 1 cm or > 1 cm), and receiver operating characteristics analysis was performed to evaluate diagnostic performance based on ADC thresholds.
  • RESULTS: Sixteen of 71 masses and 13 of 45 lesions with nonmasslike enhancement were malignant.
  • The mean ADC was significantly lower for malignant than for benign lesions for both masses (mean difference, 0.49 x 10(-3) mm(2)/s; p < 0.001) and lesions with nonmasslike enhancement (mean difference, 0.20 x 10(-3) mm(2)/s; p = 0.02).
  • The mean ADC for malignant masses (1.25 x 10(-3) mm(2)/s) was lower than that for malignant lesions with nonmasslike enhancement (1.41 x 10(-3) mm(2)/s; p = 0.07).
  • There was no relation (p > 0.05) between ADC value and lesion size for benign or malignant lesions, and there were no differences in AUC based on lesion size (p > 0.05).
  • CONCLUSION: Diffusion-weighted MRI shows promise in differentiation of benign and malignant masses and lesions with nonmasslike enhancement found at breast MRI and is not affected by lesion size.
  • [MeSH-major] Breast Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489111.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA015704
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


60. Uematsu T, Kasami M: MR imaging findings of benign and malignant circumscribed breast masses: part 2. Cystic circumscribed masses. Jpn J Radiol; 2009 Dec;27(10):405-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging findings of benign and malignant circumscribed breast masses: part 2. Cystic circumscribed masses.
  • The purpose of our study was to review the magnetic resonance (MR) imaging findings and pathological characteristics of benign and malignant cystic circumscribed breast masses.
  • This article reviews the MR imaging findings of cystic circumscribed breast masses.
  • Despite the MR imaging findings, however, many circumscribed breast masses are impossible to differentiate without performing a biopsy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Abscess / diagnosis. Breast Cyst / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Papillary / diagnosis. Female. Fibroadenoma / diagnosis. Fibrocystic Breast Disease / diagnosis. Humans. Mastitis / diagnosis. Papilloma / diagnosis. Predictive Value of Tests. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2009 Jan;35(1):21-4 [18640002.001]
  • [Cites] Histopathology. 2008 Jan;52(1):20-9 [18171414.001]
  • [Cites] Radiology. 1991 Aug;180(2):403-7 [1648757.001]
  • [Cites] Radiology. 2003 Apr;227(1):183-91 [12668745.001]
  • [Cites] Am J Surg. 2009 Apr;197(4):473-8 [18723154.001]
  • (PMID = 20035411.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


61. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 1;65(15):6640-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


62. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


63. Chowdary MV, Kalyan Kumar K, Mathew S, Rao L, Krishna CM, Kurien J: Biochemical correlation of Raman spectra of normal, benign and malignant breast tissues: a spectral deconvolution study. Biopolymers; 2009 Jul;91(7):539-46
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical correlation of Raman spectra of normal, benign and malignant breast tissues: a spectral deconvolution study.
  • The aim of this study was to understand and correlate spectral features and biochemical changes in normal, fibroadenoma and infiltrating ductal carcinoma of breast tissues using Raman spectra that were part of the spectroscopic models developed and evaluated by us earlier.
  • This study has revealed that fat (1301 and 1440 cm(-1)), collagen (1246, 1271, and 1671 cm(-1)) and DNA (1340 and 1480 cm(-1)) bands have strong presence in normal, benign and malignant breast tissues, respectively.
  • Thus the finding of this study further demonstrates the efficacy Raman spectroscopic approaches in diagnostic applications as well as in understanding molecular phenomenon in breast cancers.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Spectrum Analysis, Raman
  • [MeSH-minor] Collagen / chemistry. DNA, Neoplasm / chemistry. Female. Humans. Lipids / chemistry. Neoplasm Proteins / chemistry. Vibration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc.
  • (PMID = 19226625.001).
  • [ISSN] 0006-3525
  • [Journal-full-title] Biopolymers
  • [ISO-abbreviation] Biopolymers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Lipids; 0 / Neoplasm Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


64. Chowdary MV, Mahato KK, Kumar KK, Mathew S, Rao L, Krishna CM, Kurien J: Autofluorescence of breast tissues: evaluation of discriminating algorithms for diagnosis of normal, benign, and malignant conditions. Photomed Laser Surg; 2009 Apr;27(2):241-52
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autofluorescence of breast tissues: evaluation of discriminating algorithms for diagnosis of normal, benign, and malignant conditions.
  • OBJECTIVE: We evaluated different discriminating algorithms for classifying laser-induced fluorescence spectra of normal, benign, and malignant breast tissues that were obtained with 325-nm excitation.
  • BACKGROUND DATA: Mammography and histopathology are the conventional gold standard methods of screening and diagnosis of breast cancers, respectively.
  • Thus the development of a more reliable detection and screening methodology is of great interest to those practicing breast cancer management.
  • MATERIALS AND METHODS: Autofluorescence spectra of normal, benign, and malignant breast tissues, with 325-nm excitation, were recorded.
  • CONCLUSION: The results obtained in this study further support the efficacy of 325-nm-induced autofluorescence, and demonstrate the suitability of limit test analysis as a means of objectively and unambiguously classifying breast tissues.
  • [MeSH-major] Breast / radiation effects. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Fluorescence. Low-Level Light Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382834.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Roslind A, Johansen JS, Junker N, Nielsen DL, Dzaferi H, Price PA, Balslev E: YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl Immunohistochem Mol Morphol; 2007 Dec;15(4):371-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] YKL-40 expression in benign and malignant lesions of the breast: a methodologic study.
  • Elevated serum levels of the protein YKL-40 are associated with a poor prognosis in patients with solid and hematologic malignancies including breast cancer.
  • The aim of this study was to develop a valid reproducible immunohistochemical method to visualize YKL-40 expression in normal breast tissue as well as in benign and malignant breast lesions.
  • The presence of YKL-40 in breast tissue was verified by in situ hybridization and protein extraction procedures.
  • Ten patients with normal breast tissue and benign breast lesions and 53 patients with localized breast carcinomas were analyzed immunohistochemically.
  • The presence of YKL-40 in normal epithelial cells as well as in malignant tumor cells of the breast was established; however, a difference in staining intensity and staining pattern was observed.
  • In normal breast tissue, a weak YKL-40 immunoreactivity was found in the cytoplasm of the epithelial cells with an additional strong dotlike staining between the nucleus and the gland lumen.
  • In malignant lesions, 81% of the in situ carcinomas and 64% of the invasive carcinomas showed strong diffuse cytoplasmic YKL-40 immunoreactivity.
  • A subpopulation of cells of macrophage morphology in normal breast tissue and in malignant lesions showed strong YKL-40 immunoreactivity.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091378.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins; 0 / RNA, Messenger; 0 / Serum Albumin, Bovine; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


66. Peters NH, Vincken KL, van den Bosch MA, Luijten PR, Mali WP, Bartels LW: Quantitative diffusion weighted imaging for differentiation of benign and malignant breast lesions: the influence of the choice of b-values. J Magn Reson Imaging; 2010 May;31(5):1100-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative diffusion weighted imaging for differentiation of benign and malignant breast lesions: the influence of the choice of b-values.
  • PURPOSE: To evaluate the influence of the choice of different combinations of b-values on the ADC and on the diagnostic performance of quantitative diffusion weighted imaging (DWI) in breast lesions.
  • MATERIALS AND METHODS: Seventy-three patients (90 lesions) underwent 3 Tesla (T) breast MRI including a DWI-scan using b-values 0, 150, 499, and 1500 s/mm(2) and histological analysis.
  • The median ADC of benign lesions, noninvasive carcinomas and invasive carcinomas and the diagnostic performance of the five methods were compared.
  • RESULTS: Eighty-eight lesions were analyzed (37 benign, 13 noninvasive carcinomas, 38 invasive carcinomas).
  • The median ADC was highest in benign lesions, intermediate in noninvasive carcinomas and lowest in invasive carcinomas for all methods.
  • CONCLUSION: The ADC of breast lesions varied substantially with the choice of different b-values, indicating that absolute ADC threshold values to differentiate benign and malignant lesions should be interpreted with caution.
  • [MeSH-major] Algorithms. Breast / pathology. Breast Neoplasms / classification. Breast Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20432344.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


68. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S: Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol; 2007 Aug;88(4):271-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.
  • Conversely, both VEGFR-1 and VEGFR-2 were widely expressed in benign and neoplastic thyroid disease, suggesting that the up-regulation of VEGF and not its receptors occurs as tissue becomes autonomous.
  • [MeSH-minor] Humans. Immunoenzyme Techniques. Thyroid Neoplasms / blood supply. Thyroid Neoplasms / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] J Endocrinol. 1998 Apr;157(1):5-12 [9614352.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12 [7563203.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1569-79 [7478581.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):193-204 [8534867.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Surgery. 1996 Mar;119(3):333-9 [8619189.001]
  • [Cites] Mod Pathol. 1996 Jun;9(6):636-41 [8782200.001]
  • [Cites] J Surg Oncol. 1996 Oct;63(2):95-8 [8888801.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 15;89(2):139-47 [8998183.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):206-13 [9010092.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1968-73 [9177415.001]
  • [Cites] Br J Cancer. 1997;76(7):930-4 [9328154.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3741-7 [9360534.001]
  • [Cites] Br J Cancer. 1997;76(9):1221-7 [9365173.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):513-7 [9374227.001]
  • [Cites] J Pathol. 1998 Jan;184(1):53-7 [9582527.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1967-76 [10595926.001]
  • [Cites] Thyroid. 2000 Apr;10(4):349-57 [10807064.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):439-42 [10821490.001]
  • [Cites] J Endocrinol. 2000 Sep;166(3):475-80 [11029748.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):227-35 [11176129.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):10-7 [11172289.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):656-8 [11158026.001]
  • [Cites] IUBMB Life. 2001 Jul;52(1-2):61-6 [11795595.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4221-9 [11908675.001]
  • [Cites] Biol Chem. 2002 Oct;383(10):1573-9 [12452433.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7284-90 [12499271.001]
  • [Cites] J Mol Med (Berl). 2003 Jan;81(1):20-31 [12545246.001]
  • [Cites] Endocrinology. 2004 Feb;145(2):817-22 [14605010.001]
  • [Cites] Thyroid. 2006 Jun;16(6):545-54 [16839256.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):931-44 [16954441.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1120-4 [1279332.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Endocrinology. 1978 Dec;103(6):2306-14 [748050.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):18-32 [1372863.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1343-8 [9769366.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3908-12 [9814467.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):442-7 [9874430.001]
  • [Cites] Eur Urol. 1999 Jan;35(1):2-8 [9933788.001]
  • [Cites] J Endocrinol. 1999 Apr;161(1):41-9 [10194527.001]
  • [Cites] Hum Pathol. 1999 Aug;30(8):891-7 [10452500.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 May;115(5):1007-14 [9605068.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(11):651-6 [7525593.001]
  • (PMID = 17696908.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2517322
  •  go-up   go-down


69. Nariţa D, Raica M, Anghel A, Suciu C, Cîmpean A: Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions. Rom J Morphol Embryol; 2005;46(1):41-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions.
  • We studied 24 selected breast tumors and 3 lymph nodes metastasis from patients with breast carcinoma.
  • PSA was detected in 7% of normal breast tissues, in 54.5% of benign tumors and 46.5% of malignant tumors.
  • [MeSH-major] Breast Neoplasms / pathology. Prostate-Specific Antigen / analysis
  • [MeSH-minor] Breast / cytology. Breast Diseases / pathology. Female. Humans. Immunohistochemistry / methods. Lymphatic Metastasis / pathology. Prognosis. RNA, Messenger / genetics. Reference Values

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286983.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


70. Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J: The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer; 2007 Jan 15;96(1):110-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
  • Immunohistochemical staining for FHIT and PCNA proteins was carried out in 451 breast lesions showing nonproliferative benign breast disease (BBD) (n=263), proliferative BBD without atypia (n=128), proliferative BBD with atypia (n=11), carcinoma in situ (n=15) or invasive carcinoma (n=34) and for EGFR protein in a subset of 71 of these cases.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Neoplasm Proteins / biosynthesis. Proliferating Cell Nuclear Antigen / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1048-50 [9870850.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1378-83 [10717620.001]
  • [Cites] Gut. 1999 Aug;45(2):246-51 [10403737.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3866-9 [10463571.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9102-10 [15489891.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2056-62 [15570308.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1265-71 [15809717.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1681-5 [16030101.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1027-33 [15920544.001]
  • [Cites] Diagn Cytopathol. 2005 Oct;33(4):228-32 [16138375.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1769-72 [10974624.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:443-8 [11085938.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1227-32 [11221855.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4827-36 [11406559.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):119-30 [11438460.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3376-84 [11454885.001]
  • [Cites] JAMA. 2001 Nov 21;286(19):2441-9 [11712940.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3869-73 [11751477.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3615-20 [11891319.001]
  • [Cites] Clin Exp Metastasis. 2002;19(4):351-8 [12090476.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4054-60 [12124341.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3105-17 [12374678.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):748-54 [12473516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):187-98 [12825853.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):854-62 [14566838.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):341-9 [14973380.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3775-9 [15007172.001]
  • [Cites] J Clin Pathol. 2004 Apr;57(4):374-7 [15047740.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Feb;149(1):38-43 [15104281.001]
  • [Cites] Arch Biochem Biophys. 2004 Aug 15;428(2):160-4 [15246872.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5745-52 [15313915.001]
  • [Cites] J Natl Cancer Inst. 1991 May 1;83(9):648 [1859552.001]
  • [Cites] Science. 1995 Feb 10;267(5199):891-3 [7531366.001]
  • [Cites] Cytometry. 1994 Nov 1;17(3):258-65 [7851161.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Mar;101(2):109-15 [9494611.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):334-42 [9699523.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8613-6 [16204026.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7503-11 [16234517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10991-6 [16829574.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):267-74 [10637239.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):236-40 [9988281.001]
  • (PMID = 17164758.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / fragile histidine triad protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC2360209
  •  go-up   go-down


71. Nicholson BT, Harvey JA, Cohen MA: Nipple-areolar complex: normal anatomy and benign and malignant processes. Radiographics; 2009 Mar-Apr;29(2):509-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple-areolar complex: normal anatomy and benign and malignant processes.
  • The nipple-areolar complex may be affected by many normal variations in embryologic development and breast maturation as well as by abnormal processes of a benign or malignant nature.
  • Benign processes that may affect the nipple-areolar complex include eczema, duct ectasia, periductal mastitis, adenomas, papillomas, leiomyomas, and abscesses; malignant processes include Paget disease, lymphoma, and invasive and noninvasive breast cancers.
  • Radiologists should be aware of the best methods for evaluating each of these entities: Many disorders of the nipple-areolar complex are unique or differ in important ways from those that occur elsewhere in the breast, and they require a diagnostically specific imaging evaluation.
  • Patients may present with benign developmental variations; inversion, retraction, or enlargement of the nipple, which may have either a benign or a malignant cause; a palpable mass; nipple discharge; skin changes in and around the nipple; infection with resultant nipple changes or a subareolar mass; or abnormal findings at routine mammographic screening.
  • Further diagnostic imaging may include repeat mammography, breast ultrasonography, galactography, and magnetic resonance imaging.
  • [MeSH-major] Breast Neoplasms / diagnosis. Diagnostic Imaging / methods. Models, Anatomic. Nipples / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19325062.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


72. Ceccarelli F, Fuso A, Civitelli L, Ranieri E, Caprio G, Pagni P, Rengo M, Scarpa S: Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues. J Cancer Res Clin Oncol; 2010 Jan;136(1):157-63
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues.
  • PURPOSE: Increased expression of urokinase (uPA), a member of the serine protease family, is an effector of metastatic cascade and has been reported in various malignancies, including breast cancer. uPA overexpression in cancer tissues was correlated with a more aggressive phenotype and it is considered a strong and independent unfavorable prognostic factor in breast cancer.
  • METHODS: Using real-time PCR assay, we analyzed uPA expression of malignant and benign breast nodular lesions versus healthy tissues (normal breast and lymphocytes).
  • RESULTS: We found that besides breast cancer nodule, normal mammary gland and lymphocytes overexpressed uPA too.
  • Tissues obtained from women with benign lesions expressed homogeneous and lower uPA.
  • On the basis of these first results, uPA could be considered for further studies as a possible useful therapeutic target in breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Urokinase-Type Plasminogen Activator / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / metabolism. Female. Humans. Lymphocytes / metabolism. Middle Aged. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2340S-2344S [12163689.001]
  • [Cites] BMC Cancer. 2006 Aug 31;6:216 [16945123.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):286-92 [9766559.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):911-20 [9499455.001]
  • [Cites] Onkologie. 2008 Nov;31(11):610-4 [19145094.001]
  • [Cites] Eur J Cancer. 2006 May;42(7):811-9 [16617013.001]
  • [Cites] J Dairy Sci. 1996 Jun;79(6):1097-107 [8827475.001]
  • [Cites] Am J Clin Nutr. 1995 Mar;61(3 Suppl):659S-665S [7879734.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):443-50 [10209960.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5287-312 [17954709.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):870-80 [15515049.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):41571-9 [12198113.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):244-50 [11063652.001]
  • [Cites] BMC Cancer. 2006 Aug 18;6:211 [16916471.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):501-6 [12124797.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S46-58 [14600592.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 16;94(2):116-28 [11792750.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):511-9 [15066913.001]
  • [Cites] Pathology. 2009 Jan;41(1):40-7 [19089739.001]
  • [Cites] Am J Clin Nutr. 2000 Oct;72(4):998-1003 [11010943.001]
  • [Cites] Eur J Biochem. 1999 Jul;263(2):295-304 [10406935.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1079-88 [8635127.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):567-75 [10666386.001]
  • [Cites] J Nutr. 2006 Jun;136(6):1522-7 [16702315.001]
  • [Cites] Oncologist. 2006 Sep;11(8):857-67 [16951389.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4617-22 [12183417.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1219-27 [11021826.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):913-20 [11416112.001]
  • [Cites] J Nutr. 1998 Jul;128(7):1204-12 [9649607.001]
  • (PMID = 19826838.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


73. Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S: Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol; 2007 Jan;177(1):359-64
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
  • Our recent studies suggest that TRAIL receptor composition is the major modulator of TRAIL sensitivity, as demonstrated using prostate, breast and lung cancer cells.
  • MATERIALS AND METHODS: Paraffin embedded prostate tissues of 44 patients with benign prostatic hyperplasia, 28 with organ confined prostate carcinoma and 26 with advanced prostate carcinoma were analyzed using immunohistochemical staining procedures.
  • RESULTS: Significant levels of TRAIL-R4 decoy receptor expression were detected in patients with benign prostatic hyperplasia, and organ confined and advanced prostate carcinoma.
  • All TRAIL markers tested appear to be valuable markers for separating patients with benign prostatic hyperplasia from patients with organ confined prostate carcinoma or advanced prostate carcinoma.
  • [MeSH-major] Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / biosynthesis. TNF-Related Apoptosis-Inducing Ligand / biosynthesis

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162091.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand
  •  go-up   go-down


74. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ: Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem; 2008 Oct;54(10):1716-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues.
  • The aim of this study was to determine, as a proof of principle, whether specific candidate miRNAs could be detected in fine-needle aspirate (FNA) biopsies of pancreatic ductal adenocarcinoma (PDAC) and could accurately differentiate malignant from benign pancreatic tissues.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):470-4 [11275888.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Dig Dis. 2001;19(1):32-6 [11385249.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3581-6 [12097256.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1647-53 [12324479.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2960-71 [12784330.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5980-7 [14676123.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Cancer. 2004 Aug 25;102(4):239-46 [15368316.001]
  • [Cites] Nucleic Acids Res. 2004;32(16):e131 [15371555.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1384-90 [15316565.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):198-203 [8157358.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):953-64 [7657125.001]
  • [Cites] Gastrointest Endosc. 1997 May;45(5):387-93 [9165320.001]
  • [Cites] Gastrointest Endosc. 1997 Nov;46(5):417-23 [9402115.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3 [10367874.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2213-36 [16146690.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):119-26 [16441422.001]
  • [Cites] Pancreas. 2006 Mar;32(2):171-7 [16552337.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):754-9 [16723855.001]
  • [Cites] World J Gastroenterol. 2006 Jun 7;12(21):3344-51 [16733850.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Nov;21(11):1646-55 [16984583.001]
  • [Cites] World J Gastroenterol. 2007 Jan 14;13(2):257-63 [17226905.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):457-63 [17224927.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2344-52 [17311258.001]
  • [Cites] Pancreas. 2007 May;34(4):436-43 [17446843.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] RNA. 2007 Oct;13(10):1668-74 [17698639.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):203-11 [18403610.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • (PMID = 18719196.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075059; United States / NCI NIH HHS / CA / R21 CA133715; United States / NCI NIH HHS / CA / CA-133715
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS517274; NLM/ PMC4040292
  •  go-up   go-down


75. Ferreira E, Bertagnolli AC, Cavalcanti MF, Schmitt FC, Cassali GD: The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Vet Comp Oncol; 2009 Dec;7(4):230-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
  • The aim of this study was to assess the value of tumour size as an indicator of the differentiation of mammary neoplasias in female dogs.
  • The tumour, nodes metastates (TNM) system, based on primary lesion size, the extent of its dissemination to regional lymph nodes and the presence or absence of distant metastases, was applied to 120 female dogs diagnosed with mammary neoplasias.
  • Paraffin blocks from 38 cases were selected and studied by immunohistochemical staining for prognostic and predictive markers of breast cancer.
  • Larger tumours (T3) were mostly malignant and showed lower expression of progesterone receptor and higher expression of cellular proliferation markers.
  • This study highlights the importance of tumour size as a prognostic indicator of mammary neoplasias in female dogs.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Dog Diseases / metabolism. Gene Expression Regulation, Neoplastic / physiology. Mammary Neoplasms, Animal / pathology. Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19891693.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Roberts SS, Mendonça-Torres MC, Jensen K, Francis GL, Vasko V: GABA receptor expression in benign and malignant thyroid tumors. Pathol Oncol Res; 2009 Dec;15(4):645-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GABA receptor expression in benign and malignant thyroid tumors.
  • Neurotransmitter systems have recently been shown to be involved in multiple malignancies including breast, colon and prostate cancers.
  • [MeSH-major] Receptors, GABA / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2006 Jul;144(3):332-44 [16527506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2803-8 [17296934.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):383-90 [11144533.001]
  • [Cites] Psychoneuroendocrinology. 1987;12(1):53-9 [2884685.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):69-80 [18221027.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):61-6 [7279009.001]
  • [Cites] Endocr Dev. 2007;10:140-72 [17684395.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Cell Tissue Res. 1981;220(4):873-9 [7296659.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2270-82 [11948410.001]
  • [Cites] Life Sci. 1990;46(21):1489-501 [2162457.001]
  • [Cites] Annu Rev Neurosci. 1994;17:569-602 [7516126.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51841-50 [14530254.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):27-30 [11121859.001]
  • [Cites] Prog Exp Tumor Res. 2007;39:91-8 [17314503.001]
  • [Cites] Med Hypotheses. 2006;67(1):33-5 [16516401.001]
  • [Cites] Thyroidology. 1989 Dec;1(3):105-8 [2484871.001]
  • [Cites] J Physiol Pharmacol. 1998 Jun;49(2):303-10 [9670113.001]
  • [Cites] Neuroscience. 1996 Aug;73(3):705-13 [8809792.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):414-24 [2380337.001]
  • [Cites] Med Sci Monit. 2001 May-Jun;7(3):377-81 [11386012.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Jun;18(2):247-53 [10464715.001]
  • [Cites] Neurosci Res. 1999 Nov;35(2):145-53 [10616918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18 [15325588.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3017-24 [16303767.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):97-116 [15027888.001]
  • (PMID = 19381877.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GABARAP protein, human; 0 / Microtubule-Associated Proteins; 0 / Receptors, GABA; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B
  •  go-up   go-down


77. Siddiqui MK, Jyoti, Singh S, Mehrotra PK, Singh K, Sarangi R: Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study. Environ Int; 2006 Jul;32(5):630-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study.
  • Fifty women residing in and around New Delhi, India and identified to have benign (25 nos.) and malignant (25 nos.) breast lesions were studied for the first time to access the association between environmental exposure to lead and risk of breast cancer and to determine the potential of changes in trace elements concentration as a diagnostic marker and/or its etiological involvement in the disease.
  • Blood, tumor tissue and breast adipose tissue from tumor free area from each patient of the two groups, collected at the time of lumpectomy or mastectomy (only blood sample was collected from disease free control group), were analyzed to determine the concentration of Pb, Zn, Cu, Fe and Ca using Atomic Absorption Spectrometry.
  • Blood lead was significantly higher in malignant cases than in those of benign and control (p<0.05 each).
  • Lead level was also higher in tumor tissue when compared with their respective normal tumor free breast tissue, though non-significant, in both benign and malignant cases.
  • Interestingly, Zn, Fe, and Ca levels were higher in blood of malignant cases than in those of their benign counterparts.
  • Furthermore, these metals were also higher in tumor of malignant and benign cases as compared to normal tumor free breast tissue, many of them statistically significant (p<0.05/0.01/0.001).
  • However, Cu level was insignificantly lower in the blood and tumor tissue of malignant cases when compared with their benign counterparts while it was significantly higher (p<0.05) in tumor of benign cases when compared with those of their respective normal tumor free breast tissue.
  • There were statistically significant correlations between lead and trace element levels only in normal tumor free breast tissue of benign and malignant cases (r=0.41-0.73; p<0.05-0.001) but neither in blood nor tumor tissue of the two groups.
  • These results suggest that in the backdrop of existing experimental and epidemiological evidences exposure to lead may be one of the risk factors for breast lesions; though it warrants further investigation.
  • Further, modulation of trace elements level in both benign and malignant breast diseases patients may be of potential to be used as diagnostic marker of the disease process and its possible relationship etiologically.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Mammary Glands, Human / metabolism. Trace Elements / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580070.001).
  • [ISSN] 0160-4120
  • [Journal-full-title] Environment international
  • [ISO-abbreviation] Environ Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Trace Elements
  •  go-up   go-down


78. Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Newstead GM: Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study. Magn Reson Med; 2008 Apr;59(4):747-54
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study.
  • 3D DCE-MRI data from 100 patients with 34 benign and 79 malignant lesions were selected for review under an Institutional Review Board (IRB)-approved protocol.
  • There was a statistically significant difference between benign and malignant lesions for several model parameters: the uptake rate, initial slope, signal enhancement ratio, and curvature at the peak enhancement (at most P=0.04).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1996 Sep;200(3):639-49 [8756909.001]
  • [Cites] Radiology. 2007 Dec;245(3):684-91 [18024450.001]
  • [Cites] J Magn Reson Imaging. 1996 Sep-Oct;6(5):743-52 [8890012.001]
  • [Cites] Stat Med. 1998 May 15;17(9):1033-53 [9612889.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] Phys Med Biol. 1999 May;44(5):1147-54 [10368008.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):899-913 [10943285.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):965-74 [11105038.001]
  • [Cites] Eur Radiol. 2001;11(4):531-46 [11354744.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):376-86 [12016367.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):379-86 [12846687.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Sep;82(3):319-26 [14499978.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):487-94 [15004789.001]
  • [Cites] Magn Reson Imaging. 2004 May;22(4):467-73 [15120165.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):1066-70 [15122692.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] Radiology. 1995 Oct;197(1):33-8 [7568850.001]
  • [Cites] Radiology. 1995 Dec;197(3):743-7 [7480749.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):91-100 [8646731.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):254-9 [10508284.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Radiology. 2005 Sep;236(3):779-88 [16118160.001]
  • [Cites] Radiology. 2005 Sep;236(3):789-800 [16118161.001]
  • [Cites] Ann Intern Med. 2005 Sep 20;143(6):446-57 [16172443.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1723-32 [16714666.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):520-4 [16978965.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):104-12 [17152054.001]
  • [Cites] Magn Reson Imaging. 2007 Jun;25(5):593-603 [17540270.001]
  • [Cites] Magn Reson Imaging. 1996;14(4):337-48 [8782170.001]
  • (PMID = 18383287.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104774-01A2; United States / NCI NIH HHS / CA / R21 CA104774; United States / NCI NIH HHS / CA / R01 CA133490; United States / NCI NIH HHS / CA / R21 CA104774-01A2; United States / NCI NIH HHS / CA / R01 CA078803; United States / NCI NIH HHS / CA / 2 R01 CA078803-05A2; United States / NCI NIH HHS / CA / CA078803-07; United States / NCI NIH HHS / CA / R01 CA078803-07
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS279369; NLM/ PMC3121098
  •  go-up   go-down


79. Lü X, Li H, Xu K, Nesland JM, Suo Z: MUC-1-/ESA+ progenitor cells in normal, benign and malignant human breast epithelial cells. Histol Histopathol; 2009 11;24(11):1381-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC-1-/ESA+ progenitor cells in normal, benign and malignant human breast epithelial cells.
  • The existence of mammary epithelial stem/progenitor cells has been demonstrated in MUC-1-/ESA+ subpopulations of breast epithelial cells.
  • However, knowledge about the expression and localization in benign and malignant breast lesions is unknown.
  • Using a double-staining immunohistochemistry method, we investigated MUC-1-/ESA+ cells in 10 normal breast tissues, 49 cases with fibrocystic disease, 40 fibroadenomas, 36 invasive ductal carcinomas and the breast cancer cell lines MCF-7 and MDA-MB-468.
  • In normal breast tissues MUC-1-/ESA+ cells were mainly found in the suprabasal layer, but under the apical surface of the duct/alveolus.
  • Our results show that the MUC-1-/ESA+ subpopulation increases in fibrocystic disease within the hyperplastic areas, and varies in benign and malignant breast tumours, indicating that breast carcinogenesis may develop from malignant changes of normal MUC-1-/ESA+ cells.
  • [MeSH-major] Breast Neoplasms / pathology. Epithelial Cells / metabolism. Membrane Proteins / metabolism. Mucin-1 / metabolism. Stem Cells / cytology
  • [MeSH-minor] Breast / cytology. Breast / metabolism. Female. Fibrocystic Breast Disease / metabolism. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760587.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Mucin-1; 0 / flotillins
  •  go-up   go-down


80. Uematsu T, Kasami M: MR imaging findings of benign and malignant circumscribed breast masses: part 1. Solid circumscribed masses. Jpn J Radiol; 2009 Dec;27(10):395-404
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging findings of benign and malignant circumscribed breast masses: part 1. Solid circumscribed masses.
  • The purpose of our study was to review the magnetic resonance (MR) imaging findings and pathological diagnoses of benign and malignant solid circumscribed breast masses.
  • This article reviews the MR imaging findings of solid circumscribed breast masses.
  • A strategy for the diagnosis of solid circumscribed breast masses with MR imaging is herein presented that incorporates the signal intensity characteristics on T(1)- and T(2)-weighted images with the kinetic curve assessment reflected by the temporal and spatial uptake of contrast medium.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging. Phyllodes Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2007 Dec;189(6):1288-93 [18029860.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1421-5 [12034610.001]
  • [Cites] Radiology. 1996 Jan;198(1):121-4 [8539362.001]
  • [Cites] AJR Am J Roentgenol. 2005 Nov;185(5):1317-21 [16247156.001]
  • [Cites] Radiology. 2009 Mar;250(3):638-47 [19244039.001]
  • [Cites] Radiology. 2006 Dec;241(3):702-9 [17032912.001]
  • [Cites] Radiology. 2007 Jul;244(1):87-93 [17581897.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2006 Aug;14(3):305-28, v [17098173.001]
  • [Cites] Tumori. 1982 Jun 30;68(3):181-98 [6291202.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):628-35 [2544506.001]
  • [Cites] AJR Am J Roentgenol. 2007 Mar;188(3):691-6 [17312055.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1274-8 [15788609.001]
  • [Cites] Radiology. 2008 Jan;246(1):58-70 [18096529.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):179-83 [12076930.001]
  • [Cites] J Magn Reson Imaging. 2007 Mar;25(3):502-10 [17326093.001]
  • (PMID = 20035410.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 15
  •  go-up   go-down


81. Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, Husnjak K, Unusic J, Pavelic K: Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol; 2005 Aug;79(1):42-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
  • The aims of this study were to assess the expression of protein products of c-myc, erbB-2, p53 and nm23-H1 gene in benign and malignant breast lesions, to estimate their possible coexpression and to correlate the results of immunohistochemical analysis with various clinicopathologic parameters.
  • Expression of c-myc protein was high in both malignant and benign lesions (95% and 100%).
  • Expression of erbB-2 and mutated p53 proteins in malignant lesions was 27% and 34%.
  • These proteins were present in benign lesions as well: 7.8% of benign lesions were positive for erbB-2 protein and 19.6% for p53 protein.
  • The expression of nm23-H1 protein was similar in benign and malignant lesions: 47% and 54%.
  • We also found a negative correlation between the size of breast carcinomas and the expression of nm23-H1, a higher proportion of nm23-H1-positive carcinomas in the group of erbB-2-negative, p53-negative carcinomas and a higher proportion of nm23-H1-positive carcinomas in the group of malignant lesions with negative axillary lymph nodes.
  • Our results support the hypothesis that in women with breast cancer the expression of nm23-H1 gene may contribute to more favorable phenotype.
  • We also showed that some changes found in malignant breast tumors such as the presence of mutated p53 protein and the expression of erbB-2 protein may be found in benign lesions as well.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Nucleoside-Diphosphate Kinase / biosynthesis. Proto-Oncogene Proteins c-myc / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Breast Diseases / metabolism. Breast Diseases / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Mutation. NM23 Nucleoside Diphosphate Kinases. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005711.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


82. Carder PJ, Garvican J, Haigh I, Liston JC: Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast. Histopathology; 2005 Mar;46(3):320-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.
  • The appropriate management of non-malignant papillary breast lesions detected on needle core biopsy (NCB) is currently uncertain.
  • METHODS AND RESULTS: Forty-seven papillary breast lesions with a histological diagnosis of papilloma, papilloma with atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS), multiple papillomas, 'papillomatosis' or papillary carcinoma (invasive or in situ) were identified from records at the Leeds Breast Screening and Assessment Unit.
  • In 21 cases the previous NCB contained a papillary proliferation which had been categorized as either 'B2', benign, 'B3', of uncertain malignant potential, or 'B4', suspicious of malignancy.
  • All cases with a previous 'B4' were malignant on subsequent excision.
  • All excised cases with a previous 'B3' or 'B2' were found benign, although four of the 'B3's derived from papillomata associated with an atypical proliferation amounting to ADH.
  • CONCLUSION: Our results confirm the accuracy of NCB in the diagnosis of screen-detected papillary lesions of the breast.
  • [MeSH-major] Biopsy, Needle / standards. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology. Papilloma / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Breast / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Middle Aged. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2006 Jul;49(1):91 [16842253.001]
  • (PMID = 15720418.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Del Frate C, Bestagno A, Cerniato R, Soldano F, Isola M, Puglisi F, Bazzocchi M: Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value. Radiol Med; 2006 Sep;111(6):783-96
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value.
  • PURPOSE: The purpose of this study was to evaluate whether lesion size may influence the value of sonographic findings in the differential diagnosis between benign or malignant breast lesions.
  • MATERIALS AND METHODS: Sonographic features of 256 histologically confirmed (148 benign, 108 malignant) breast lesions were retrospectively and independently reviewed by three radiologists unaware of mammographic findings and pathology results.
  • The accuracy of breast sonography in characterising solid lesions was also evaluated.
  • RESULTS: Analysis of the sonographic features predictive of malignant disease, taken as a whole, showed that only irregular margins and marked hypoechogenicity maintain their predictive value independent of lesion size.
  • Accuracy of breast sonography improved when evaluating lesions larger than 7 mm.
  • CONCLUSIONS: Lesion size influences the value of sonographic findings in distinguishing benign from malignant lesions.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896562.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


84. Furman-Haran E, Schechtman E, Kelcz F, Kirshenbaum K, Degani H: Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer; 2005 Aug 15;104(4):708-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions.
  • The objective of the current study was to quantify the microvascular perfusion parameters in various human breast lesions and to determine whether they varied between benign lesions and malignancy and whether they were altered with increased invasiveness.
  • METHODS: Perfusion parameters in 22 benign fibrocystic changes, 15 ductal carcinomas in situ (DCIS), 30 infiltrating ductal carcinomas (IDC), and 22 fibroadenomas were measured using high-resolution DCE-MRI.
  • Logistic regression analysis evaluated the best predictors of the kinetic parameters that differentiate between IDC and benign lesions.
  • RESULTS: The perfusion parameters exhibited a progressive increase from benign fibrocystic changes to DCIS and IDC, with a significant correlation between lesion type and the parameters' values (range of correlation coefficients, 0.56-0.76; P < 0.0001).
  • Stepwise logistic regression selected k(trans) as the best predictor for distinguishing benign fibrocystic changes from IDC, yielding 93% sensitivity and 96% specificity.
  • CONCLUSIONS: The microvascular perfusion parameters in breast lesions were elevated with invasiveness.
  • Quantification of these parameters using high-resolution DCE-MRI was helpful for differentiating between breast lesions and should improve breast carcinoma diagnosis.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / radiography. Carcinoma, Ductal, Breast / blood supply. Carcinoma, Ductal, Breast / radiography. Neovascularization, Pathologic / radiography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15971199.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Cha JH, Moon WK, Cho N, Kim SM, Park SH, Han BK, Choe YH, Park JM, Im JG: Characterization of benign and malignant solid breast masses: comparison of conventional US and tissue harmonic imaging. Radiology; 2007 Jan;242(1):63-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses: comparison of conventional US and tissue harmonic imaging.
  • PURPOSE: To prospectively compare the diagnostic performance of radiologists by using conventional ultrasonography (US) and tissue harmonic imaging for the differentiation of benign from malignant solid breast masses, with histologic results used as the reference standard.
  • Images were obtained with conventional US and tissue harmonic imaging in 88 patients (age range, 25-67 years; mean age, 45 years) with 91 solid breast masses (30 cancers and 61 benign lesions) before excisional or needle biopsy.
  • CONCLUSION: The performance of the radiologists with respect to the characterization of solid breast masses as benign or malignant was not significantly improved with tissue harmonic imaging.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / ultrasonography. Image Enhancement / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) RSNA, 2006.
  • (PMID = 17090709.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Lipnick S, Liu X, Sayre J, Bassett LW, Debruhl N, Thomas MA: Combined DCE-MRI and single-voxel 2D MRS for differentiation between benign and malignant breast lesions. NMR Biomed; 2010 Oct;23(8):922-30
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined DCE-MRI and single-voxel 2D MRS for differentiation between benign and malignant breast lesions.
  • The metabolite ratios from the 2D MRS spectra were analyzed using multivariate statistical analyses to determine a method capable of automatic separation of the patient cohort into malignant and benign lesions.
  • Analysis of the 2D MRS data demonstrated a significant difference (p < 0.05) in 12 of 18 metabolite ratios analyzed for malignant compared to benign lesions.
  • Using the Classification and Regression Tree (CART) statistical analysis the resulting sensitivity and specificity were 100% and 91%, respectively, with the most accurate predictor for differentiating malignant and benign determined to be FAT/FMETD.
  • The results suggest improved breast cancer detection through the combination of morphological and enhancement information from DCE-MRI and metabolic information from 2D MRS.
  • [MeSH-major] Breast Neoplasms. Contrast Media / metabolism. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20878970.001).
  • [ISSN] 1099-1492
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; N91BDP6H0X / Choline
  •  go-up   go-down


87. Padilla-Rodriguez AL, Padilla-Villalta A, Arandia Y: Synchronous benign and malignant mesenchymal breast tumor. Breast J; 2007 May-Jun;13(3):314-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous benign and malignant mesenchymal breast tumor.
  • [MeSH-major] Breast Neoplasms / pathology. Liposarcoma, Myxoid / pathology. Mesenchymoma / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Breast Diseases / pathology. Female. Fibroma / pathology. Granular Cell Tumor / pathology. Humans. Middle Aged

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461913.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Chen ST, Hsiao YH, Huang YL, Kuo SJ, Tseng HS, Wu HK, Chen DR: Comparative analysis of logistic regression, support vector machine and artificial neural network for the differential diagnosis of benign and malignant solid breast tumors by the use of three-dimensional power Doppler imaging. Korean J Radiol; 2009 Sep-Oct;10(5):464-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of logistic regression, support vector machine and artificial neural network for the differential diagnosis of benign and malignant solid breast tumors by the use of three-dimensional power Doppler imaging.
  • OBJECTIVE: Logistic regression analysis (LRA), Support Vector Machine (SVM) and a neural network (NN) are commonly used statistical models in computer-aided diagnostic (CAD) systems for breast ultrasonography (US).
  • MATERIALS AND METHODS: A database that contained 3D power Doppler imaging pairs of non-harmonic and tissue harmonic images for 97 benign and 86 malignant solid tumors was utilized.
  • The virtual organ computer-aided analysis-imaging program was used to analyze the stored volumes of the 183 solid breast tumors.
  • LRA, an SVM and NN were employed in comparative analyses for the characterization of benign and malignant solid breast masses from the database.
  • [MeSH-major] Artificial Intelligence. Breast Neoplasms / ultrasonography. Imaging, Three-Dimensional / statistics & numerical data. Neural Networks (Computer). Ultrasonography, Doppler / statistics & numerical data. Ultrasonography, Mammary / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Nov;213(2):317-20 [10551208.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Jul;32(1):97-102 [18521971.001]
  • [Cites] Semin Ultrasound CT MR. 2000 Aug;21(4):308-16 [11014253.001]
  • [Cites] Clin Imaging. 2001 Nov-Dec;25(6):379-84 [11733148.001]
  • [Cites] Korean J Radiol. 2002 Jan-Mar;3(1):38-44 [11919477.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):433-8 [12017328.001]
  • [Cites] Ultrasound Obstet Gynecol. 2002 Sep;20(3):281-5 [12230453.001]
  • [Cites] Ultrasound Med Biol. 2002 Oct;28(10):1301-10 [12467857.001]
  • [Cites] Radiology. 2003 Feb;226(2):504-14 [12563146.001]
  • [Cites] Acad Radiol. 2003 Feb;10(2):189-97 [12583571.001]
  • [Cites] Arch Surg. 2003 Mar;138(3):296-302 [12611578.001]
  • [Cites] J Ultrasound Med. 2003 May;22(5):479-87; quiz 488- 9 [12751859.001]
  • [Cites] Ultrasound Med Biol. 2003 May;29(5):679-86 [12754067.001]
  • [Cites] Ultrasound Med Biol. 2003 Sep;29(9):1273-9 [14553804.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Oct;23(10):1292-300 [15493696.001]
  • [Cites] Acad Radiol. 2005 Apr;12(4):487-95 [15831423.001]
  • [Cites] Clin Imaging. 2005 May-Jun;29(3):179-84 [15855062.001]
  • [Cites] Ultrasound Obstet Gynecol. 2006 Sep;28(3):325-9 [16906635.001]
  • [Cites] Radiology. 2007 Apr;243(1):56-62 [17312276.001]
  • [Cites] Comput Methods Programs Biomed. 2007 Oct;88(1):75-84 [17719122.001]
  • [Cites] Ultrasound Med Biol. 2008 Jan;34(1):88-95 [17720297.001]
  • [Cites] Korean J Radiol. 2008 Mar-Apr;9(2):111-8 [18385557.001]
  • [Cites] Radiology. 1999 Nov;213(2):407-12 [10551220.001]
  • (PMID = 19721831.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2731864
  • [Keywords] NOTNLM ; Flow index / Logistic regression analysis / Neural network / Support Vector Machine / Vascularization index / Vascularization-flow index
  •  go-up   go-down


89. Ikeda S, Shibata T, Funakoshi N: Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast. Rinsho Byori; 2005 Jun;53(6):487-93
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast.
  • Telomerase activity is associated with immortality and is expressed in various malignant tumors.
  • In this study, the expression of TERT was investigated by immunocytochemistry to determine whether it is a useful marker for differential diagnosis in benign or malignant breast tumors.
  • We examined imprint smears prepared from 63 surgically resected breast lesions, and 27 cases of secretion or aspiration cytology smears had been routinely diagnosed.
  • In imprint smears and routine cytology smears, TERT-positive cases significantly tended to be malignant cases (p=0.014, p=0.033 respectively).
  • Especially, in malignant imprint smear cases, positive expression of TERT was significantly correlated with lymph node metastasis (p=0.022).
  • In conclusion, the expression of TERT protein might be a useful marker for differential diagnosis in malignant and benign breast tumors.
  • In malignant cases, it could be a useful indicator for the assessment of potential of lymph node metastasis [corrected].
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. DNA-Binding Proteins / analysis. Telomerase / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rinsho Byori.2005 Aug;53(8):748
  • (PMID = 16026073.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


90. Li X, Huang W, Yankeelov TE, Tudorica A, Rooney WD, Springer CS Jr: Shutter-speed analysis of contrast reagent bolus-tracking data: Preliminary observations in benign and malignant breast disease. Magn Reson Med; 2005 Mar;53(3):724-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shutter-speed analysis of contrast reagent bolus-tracking data: Preliminary observations in benign and malignant breast disease.
  • Here, the standard and shutter-speed models are applied to B-T data obtained from routine human breast examinations.
  • The size of the mismatch is considerably greater for the IDC lesions than for the FA lesions, causing the shutter-speed model to exhibit improved discrimination of malignant IDC tumors from the benign FA lesions compared with the standard model.
  • Furthermore, the shutter-speed model clearly reveals focal "hot spots" of elevated CR perfusion/permeation present in only the malignant tumors.
  • [MeSH-major] Breast Diseases / metabolism. Carcinoma, Ductal, Breast / metabolism. Contrast Media / pharmacokinetics. Fibroadenoma / metabolism. Gadolinium DTPA / pharmacokinetics
  • [MeSH-minor] Breast Neoplasms / metabolism. Female. Humans. Image Processing, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15723402.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB 00422; United States / NINDS NIH HHS / NS / R01 NS 40801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


91. Chen G, Zou Q, Yang Z: [Expression of galectin-3 and Sambucus nigra agglutinin and its clinicopathological significance in benign and malignant lesions of breast]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jun;35(6):584-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of galectin-3 and Sambucus nigra agglutinin and its clinicopathological significance in benign and malignant lesions of breast].
  • OBJECTIVE: To detect the expression of galectin-3 (gal-3) and Sambucus nigra agglutinin (SNA) and determine their clinicopathological significance in breast cancers and benign breast lesions.
  • METHODS: Envison immunohistochemistry for staining gal-3 expression, and ABC affinity-cytochemistry to detect SNA expression were used in paraffin-embedded slides from specimens of breast cancers (n=60) and benign lesions (n=30).
  • RESULTS: The positive rates and scoring means of gal-3 and SNA were significantly higher in breast cancer (48.3%, 2.07 +/- 2.25, 2.12 +/- 2.26) than those in benign lesions (26.7%, 1.03 +/- 1.63, 1.07 +/- 1.59, P < 0.05).
  • The scoring means of gal-3 and SNA expression were significantly lower in the positive cases of estrogen receptor (ER) and the negative ones of CA15-3 than those in the negative cases and the positive ones (P < 0.05).The survival analysis of Kaplan-Meier showed the 5-year survival rate and mean survival period were significantly lower in the gal-3 or SNA expression positive cases than those in the negative cases of breast cancer (P<0.01).
  • CONCLUSION: The expressive level of gal-3 and SNA lectins might have important effect on the carcinogenesis, progression and biologic behaviors of breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Fibrocystic Breast Disease / metabolism. Galectin 3 / metabolism. Plant Lectins / metabolism. Ribosome Inactivating Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622331.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Galectin 3; 0 / Mucin-1; 0 / Plant Lectins; 0 / Receptors, Estrogen; 0 / Sambucus nigra lectins; EC 3.2.2.22 / Ribosome Inactivating Proteins
  •  go-up   go-down


92. Ricci P, Cantisani V, Ballesio L, Pagliara E, Sallusti E, Drudi FM, Trippa F, Calascibetta F, Erturk SM, Modesti M, Passariello R: Benign and malignant breast lesions: efficacy of real time contrast-enhanced ultrasound vs. magnetic resonance imaging. Ultraschall Med; 2007 Feb;28(1):57-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant breast lesions: efficacy of real time contrast-enhanced ultrasound vs. magnetic resonance imaging.
  • PURPOSE: To assess the efficacy of low mechanical index (MI) real time grey scale contrast-enhanced US (CEUS) in the differentiation of breast lesions in comparison to Magnetic Resonance Imaging (MRI).
  • According to the different contrast enhancement patterns and the resulting perfusion maps, all the malignant lesions and 9 out of 12 benign lesions were correctly diagnosed, thus resulting in 87.5 % of specificity and 100 % of sensitivity.
  • The three lesions which were incorrectly classified as malignant were two hypervascularised fibroadenomas in young women and a phylloides tumour.
  • CONCLUSION: CEUS seems to be a reliable method to differentiate breast lesions, since it provides typical enhancement patterns.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Diseases / ultrasonography. Breast Neoplasms / diagnosis. Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / ultrasonography. Contrast Media. Diagnosis, Differential. Female. Fibroadenoma / ultrasonography. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging / methods. Male. Middle Aged. Sensitivity and Specificity. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304413.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


93. Bulut AS, Erden E, Sak SD, Doruk H, Kursun N, Dincol D: Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch; 2005 Jul;447(1):24-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases.
  • The role of calcium independent inducible nitric oxide synthase (iNOS) in breast carcinoma is controversial, and the implications of iNOS expression on prognosis are not known.
  • In addition, 11 normal breast tissues, 20 cases of usual ductal hyperplasias (UDHs) and 20 fibroadenomas were included.
  • We found that 78% of malignant and 75% of benign cases showed iNOS immunoreactivity.
  • However, the intensity and the quantity of iNOS expression were significantly higher in the cancer group when compared with benign breasts (P<0.001), suggesting a role of iNOS in breast carcinogenesis.
  • As strong iNOS expression was correlated with short DFS, we concluded that further studies would be necessary to elucidate if iNOS expression might be a useful prognostic marker in breast carcinoma, especially in the axilla negative group.
  • [MeSH-major] Breast / enzymology. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Fibroadenoma / enzymology. Nitric Oxide Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1999 Jun;14(6):1069-73 [10339659.001]
  • [Cites] J Surg Oncol. 1999 Apr;70(4):222-9 [10219017.001]
  • [Cites] APMIS. 2003 Dec;111(12):1137-46 [14678024.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1191-8 [12216084.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):145-51 [10573107.001]
  • [Cites] Urol Oncol. 2003 Mar-Apr;21(2):117-22 [12856639.001]
  • [Cites] Cancer. 1998 May 15;82(10):1897-903 [9587122.001]
  • [Cites] Virchows Arch. 2000 Dec;437(6):662-6 [11193479.001]
  • [Cites] Hypertension. 1994 Jun;23(6 Pt 2):1121-31 [7515853.001]
  • [Cites] Acta Neuropathol. 2003 Apr;105(4):333-40 [12624786.001]
  • [Cites] J Clin Pathol. 2000 Aug;53(8):634-5 [11002770.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):880-6 [10970689.001]
  • [Cites] Scand J Gastroenterol. 2000 Nov;35(11):1204-11 [11145294.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):725-8 [14991947.001]
  • [Cites] Am Surg. 2001 Jul;67(7):709-13 [11450795.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):30-9 [10728591.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4768-75 [11156233.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Oct;32(5):534-8 [14759114.001]
  • [Cites] Asian J Surg. 2004 Jan;27(1):10-7 [14719508.001]
  • [Cites] BJU Int. 2000 Aug;86(3):234-9 [10930922.001]
  • [Cites] Lab Invest. 1999 Oct;79(10):1215-25 [10532585.001]
  • [Cites] Essays Biochem. 1997;32:61-72 [9493011.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):521-4 [11956620.001]
  • [Cites] Ai Zheng. 2003 Sep;22(9):978-81 [12969533.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):619-23 [12943630.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):265-71 [15661552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):217-21 [12909236.001]
  • [Cites] Arch Surg. 1999 Mar;134(3):245-51 [10088562.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Aug;17(8):914-21 [12164968.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Ann Anat. 2003 Dec;185(6):549-54 [14704000.001]
  • [Cites] J Zhejiang Univ Sci. 2003 Mar-Apr;4(2):221-7 [12659238.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):534-41 [9716040.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2408-16 [10873093.001]
  • [Cites] Laryngoscope. 2002 Jun;112(6):1084-8 [12160278.001]
  • [Cites] Virchows Arch. 2000 Feb;436(2):109-14 [10755599.001]
  • (PMID = 15947943.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


94. Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P: Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology. J Nucl Med; 2008 Sep;49(9):1429-36
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
  • Our objective was to evaluate features of these foci associated with benign or malignant etiology.
  • On univariate analysis, variables associated with malignancy were SUV max (6.6+/-4.1 vs. 3.5+/-1.0 for benign, P<0.001; t test); impurity (P<0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P=0.027); and change in uptake between scans 1 and 2 (change in SUV=2.7+/-2.1 vs. 0.73+/-1.1 for benign, P < 0.01; t test).
  • Variables associated with benign etiology were: symmetry (difference between left and right sides=0.57+/-0.54 for benign vs. 1.8+/-1.7 for malignant, P<0.01), purity, and colorectal primary (75% of colorectal were benign vs. 34% of breast, 49% of lymphoma, and 37% of other, P=0.030; chi(2) test).
  • CONCLUSION: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a benign etiology.
  • [MeSH-major] Artifacts. Fluorodeoxyglucose F18. Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2009 Mar;50(3):489-90 [19223415.001]
  • (PMID = 18765585.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


95. Campos LF, Silva AC, Barros AK: Independent component analysis and neural networks applied for classification of malignant, benign and normal tissue in digital mammography. Methods Inf Med; 2007;46(2):212-5
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent component analysis and neural networks applied for classification of malignant, benign and normal tissue in digital mammography.
  • OBJECTIVES: This paper proposes an efficient method for the discrimination and classification of mammograms with benign, malignant and normal tissues.
  • [MeSH-major] Breast / physiology. Breast Neoplasms / diagnosis. Image Processing, Computer-Assisted. Mammography. Neural Networks (Computer). Radiographic Image Enhancement. Signal Processing, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347758.001).
  • [ISSN] 0026-1270
  • [Journal-full-title] Methods of information in medicine
  • [ISO-abbreviation] Methods Inf Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Baltzer PA, Kaiser CG, Dietzel M, Vag T, Herzog AB, Gajda M, Camara O, Kaiser WA: Value of ductal obstruction sign in the differentiation of benign and malignant breast lesions at MR imaging. Eur J Radiol; 2010 Aug;75(2):e18-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of ductal obstruction sign in the differentiation of benign and malignant breast lesions at MR imaging.
  • PURPOSE: MR-Mammography (MRM) is regarded as the most sensitive method for detection of breast cancer without a broad consensus on specificity.
  • Malignancy was found in two cases (one invasive ductal carcinoma and one DCIS) and benign tissue in 18 cases (15 papillomas).
  • Because of the clear association with benign lesions, benign lesions showing ductal obstruction were characterized as true positive findings.
  • DISCUSSION: If ductal obstruction is found to be positive, the associated lesion is most likely benign.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammary Glands, Human / pathology
  • [MeSH-minor] Adolescent. Adult. Aged, 80 and over. Breast / pathology. Breast Diseases / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19954911.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


97. Auvinen P, Tammi R, Tammi M, Johansson R, Kosma VM: Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology; 2005 Oct;47(4):420-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan.
  • AIMS: To examine the expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in breast lesions, and to correlate it with the expression of hyaluronan (HA).
  • METHODS AND RESULTS: CD 44 expression was studied in 75 breast tissue samples, consisting of benign, premalignant and malignant breast lesions, using immunohistochemistry.
  • CD 44 s, but not CD 44 v 3 or CD 44 v 6, was found in the stromal cells, and it was similar in benign and malignant tumours.
  • In benign lesions CD 4 v 6 was detected in 20-30% of the ductal epithelial cells, while C 44 v 3 and CD 44 s were not expressed.
  • CD 44 and HA expression levels were not closely linked in the benign or malignant breast lesions, because HA was overexpressed later in breast cancer progression than CD 44.
  • However, in breast carcinomas CD 44 and HA positivity was often found in the same areas of the sections, and the dual staining confirmed actual colocalization of CD 44 s and HA in the same cells.
  • CONCLUSIONS: CD 44 s, CD 44 v 3 and CD 44 v 6 are up-regulated earlier than HA in breast carcinoma progression, and in later stages they often colocalize with cell surface HA.
  • [MeSH-major] Antigens, CD44 / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Hyaluronic Acid / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178897.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


98. Noonan AM, Carney DN, McCaffrey J: Review of neoplastic brachial plexopathy at the Mater Misericordiae University Hospital, Ireland. J Clin Oncol; 2009 May 20;27(15_suppl):e20681

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20681 Background: Neoplastic brachial plexopathy (NBP) may occur with benign or malignant neoplasms.
  • 18 MRIs were performed in patients with a known cancer diagnosis, 1 was performed in a patient with a benign thymoma, 1 with a neurofibroma and the remaining 17 MRIs were ordered for other conditions.
  • Of the 20 MRIs performed (18 in patients with cancer, 2 in patients with a history of benign neoplasms), 6 (30%) confirmed a diagnosis of NBP.
  • 27.8% (5/18) of patients with a diagnosis of cancer had NBP (3 had metastatic breast cancer, 2 had non-small cell lung cancer (NSCLC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Lazebnik M, Popovic D, McCartney L, Watkins CB, Lindstrom MJ, Harter J, Sewall S, Ogilvie T, Magliocco A, Breslin TM, Temple W, Mew D, Booske JH, Okoniewski M, Hagness SC: A large-scale study of the ultrawideband microwave dielectric properties of normal, benign and malignant breast tissues obtained from cancer surgeries. Phys Med Biol; 2007 Oct 21;52(20):6093-115
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large-scale study of the ultrawideband microwave dielectric properties of normal, benign and malignant breast tissues obtained from cancer surgeries.
  • The development of microwave breast cancer detection and treatment techniques has been driven by reports of substantial contrast in the dielectric properties of malignant and normal breast tissues.
  • However, definitive knowledge of the dielectric properties of normal and diseased breast tissues at microwave frequencies has been limited by gaps and discrepancies across previously published studies.
  • To address these issues, we conducted a large-scale study to experimentally determine the ultrawideband microwave dielectric properties of a variety of normal, malignant and benign breast tissues, measured from 0.5 to 20 GHz using a precision open-ended coaxial probe.
  • Previously, we reported the dielectric properties of normal breast tissue samples obtained from reduction surgeries.
  • Here, we report the dielectric properties of normal (adipose, glandular and fibroconnective), malignant (invasive and non-invasive ductal and lobular carcinomas) and benign (fibroadenomas and cysts) breast tissue samples obtained from cancer surgeries.
  • Our analyses show that the contrast in the microwave-frequency dielectric properties between malignant and normal adipose-dominated tissues in the breast is considerable, as large as 10:1, while the contrast in the microwave-frequency dielectric properties between malignant and normal glandular/fibroconnective tissues in the breast is no more than about 10%.
  • [MeSH-major] Breast / physiopathology. Breast Neoplasms / physiopathology. Microwaves. Models, Biological

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17921574.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 087007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


100. Fischer D, Becker S, Cordes T, Bücker B, Diedrich K, Friedrich M, Salehin D, Thill M: Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer Res; 2009 Sep;29(9):3641-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines.
  • The expression of 24-OHase in cells and breast tissue was investigated and its splice variants were detected.
  • The expression of 24-OHase was reduced by about 57% in MCF-7 breast cancer cells, compared to MCF-10F benign breast cells.
  • In the breast cancer tissue, the expression of 24-OHase was reduced by about 58% compared to benign tissue.
  • However, in the Western blot, only one signal was found in the benign tissue at 56 kDa, while in malignant tissue, a further band was detected at 40 kDa.
  • [MeSH-major] Breast / enzymology. Breast Neoplasms / enzymology. Steroid Hydroxylases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667160.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  •  go-up   go-down






Advertisement